UniProtKB - P04439 (HLAA_HUMAN)
(max 400 entries)
Your basket is currently empty. i <p>When browsing through different UniProt proteins, you can use the ‘basket’ to save them, so that you can back to find or analyse them later.<p><a href='/help/basket' target='_top'>More...</a></p>
Select item(s) and click on "Add to basket" to create your own collection here
(400 entries max)
>sp|P04439|HLAA_HUMAN HLA class I histocompatibility antigen, A alpha chain OS=Homo sapiens OX=9606 GN=HLA-A PE=1 SV=2 MAVMAPRTLLLLLSGALALTQTWAGSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRF DSDAASQRMEPRAPWIEQEGPEYWDQETRNVKAQSQTDRVDLGTLRGYYNQSEAGSHTIQ IMYGCDVGSDGRFLRGYRQDAYDGKDYIALNEDLRSWTAADMAAQITKRKWEAAHEAEQL RAYLDGTCVEWLRRYLENGKETLQRTDPPKTHMTHHPISDHEATLRCWALGFYPAEITLT WQRDGEDQTQDTELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWEL SSQPTIPIVGIIAGLVLLGAVITGAVVAAVMWRRKSSDRKGGSYTQAASSDSAQGSDVSL TACKVHelp videoAdd a publicationFeedback
Protein
HLA class I histocompatibility antigen, A alpha chain
Gene
HLA-A
Organism
Homo sapiens (Human)
Status
Reviewed-Annotation score:
Annotation score:5 out of 5
<p>The annotation score provides a heuristic measure of the annotation content of a UniProtKB entry or proteome. This score <strong>cannot</strong> be used as a measure of the accuracy of the annotation as we cannot define the ‘correct annotation’ for any given protein.<p><a href='/help/annotation_score' target='_top'>More...</a></p>-Experimental evidence at protein leveli <p>This indicates the type of evidence that supports the existence of the protein. Note that the ‘protein existence’ evidence does not give information on the accuracy or correctness of the sequence(s) displayed.<p><a href='/help/protein_existence' target='_top'>More...</a></p>Select a section on the left to see content.
<p>This section provides any useful information about the protein, mostly biological knowledge.<p><a href='/help/function_section' target='_top'>More...</a></p>Functioni
Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumor-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-A-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells (PubMed:2456340, PubMed:2784196, PubMed:1402688, PubMed:7504010, PubMed:9862734, PubMed:10449296, PubMed:12138174, PubMed:12393434, PubMed:15893615, PubMed:17189421, PubMed:19543285, PubMed:21498667, PubMed:24192765, PubMed:7694806, PubMed:24395804, PubMed:28250417). May also present self-peptides derived from the signal sequence of secreted or membrane proteins, although T cells specific for these peptides are usually inactivated to prevent autoreactivity (PubMed:25880248, PubMed:7506728, PubMed:7679507). Both the peptide and the MHC molecule are recognized by TCR, the peptide is responsible for the fine specificity of antigen recognition and MHC residues account for the MHC restriction of T cells (PubMed:12796775, PubMed:18275829, PubMed:19542454, PubMed:28250417). Typically presents intracellular peptide antigens of 8 to 13 amino acids that arise from cytosolic proteolysis via IFNG-induced immunoproteasome or via endopeptidase IDE/insulin-degrading enzyme (PubMed:17189421, PubMed:20364150, PubMed:17079320, PubMed:26929325, PubMed:27049119). Can bind different peptides containing allele-specific binding motifs, which are mainly defined by anchor residues at position 2 and 9 (PubMed:7504010, PubMed:9862734).26 Publications
<p>Manually curated information for which there is published experimental evidence.</p> <p><a href="/manual/evidences#ECO:0000269">More...</a></p> Manual assertion based on experiment ini
- Ref.37"Analysis of the molecular basis of HLA-A3 recognition by cytotoxic T cells using defined mutants of the HLA-A3 molecule."
Jelachich M.L., Cowan E.P., Turner R.V., Coligan J.E., Biddison W.E.
J. Immunol. 141:1108-1113(1988) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*03:01), CHARACTERIZATION OF VARIANT VAL-176. - Ref.38"Polymorphism in the alpha 3 domain of HLA-A molecules affects binding to CD8."
Salter R.D., Norment A.M., Chen B.P., Clayberger C., Krensky A.M., Littman D.R., Parham P.
Nature 338:345-347(1989) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES A*02:01 AND A*68:01), INTERACTION WITH CD8A, DOMAIN, CHARACTERIZATION OF VARIANT VAL-269. - Ref.39"A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E."
Traversari C., van der Bruggen P., Luescher I.F., Lurquin C., Chomez P., Van Pel A., De Plaen E., Amar-Costesec A., Boon T.
J. Exp. Med. 176:1453-1457(1992) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*01:01). - Ref.40"HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs."
DiBrino M., Tsuchida T., Turner R.V., Parker K.C., Coligan J.E., Biddison W.E.
J. Immunol. 151:5930-5935(1993) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES A*01:01 AND A*03:01), INTERACTION WITH B2M AND PEPTIDE. - Ref.41"Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides."
DiBrino M., Parker K.C., Shiloach J., Knierman M., Lukszo J., Turner R.V., Biddison W.E., Coligan J.E.
Proc. Natl. Acad. Sci. U.S.A. 90:1508-1512(1993) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*03:01), INTERACTION WITH B2M AND PEPTIDE. - Ref.42"Endogenous peptides with distinct amino acid anchor residue motifs bind to HLA-A1 and HLA-B8."
DiBrino M., Parker K.C., Shiloach J., Turner R.V., Tsuchida T., Garfield M., Biddison W.E., Coligan J.E.
J. Immunol. 152:620-631(1994) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*01:01), INTERACTION WITH B2M AND PEPTIDE. - Ref.47"Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles."
Kawakami Y., Robbins P.F., Wang X., Tupesis J.P., Parkhurst M.R., Kang X., Sakaguchi K., Appella E., Rosenberg S.A.
J. Immunol. 161:6985-6992(1998) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*03:01). - Ref.48"HLA-A*1101-restricted cytotoxic T lymphocyte recognition of HIV-1 Pol protein."
Fukada K., Chujoh Y., Tomiyama H., Miwa K., Kaneko Y., Oka S., Takiguchi M.
AIDS 13:1413-1414(1999) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*11:01). - Ref.51"Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations."
Nagata Y., Ono S., Matsuo M., Gnjatic S., Valmori D., Ritter G., Garrett W., Old L.J., Mellman I.
Proc. Natl. Acad. Sci. U.S.A. 99:10629-10634(2002) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*02:01). - Ref.52"Tetramer-assisted identification and characterization of epitopes recognized by HLA A*2402-restricted Epstein-Barr virus-specific CD8+ T cells."
Kuzushima K., Hayashi N., Kudoh A., Akatsuka Y., Tsujimura K., Morishima Y., Tsurumi T.
Blood 101:1460-1468(2003) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*24:02). - Ref.53"Identification and characterization of HIV-1-specific CD8+ T cell epitopes presented by HLA-A*2601."
Satoh M., Takamiya Y., Oka S., Tokunaga K., Takiguchi M.
Vaccine 23:3783-3790(2005) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*26:01). - Ref.54"Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1."
Asemissen A.M., Keilholz U., Tenzer S., Mueller M., Walter S., Stevanovic S., Schild H., Letsch A., Thiel E., Rammensee H.G., Scheibenbogen C.
Clin. Cancer Res. 12:7476-7482(2006) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*01:01). - Ref.56"Role of immunoproteasome catalytic subunits in the immune response to hepatitis B virus."
Robek M.D., Garcia M.L., Boyd B.S., Chisari F.V.
J. Virol. 81:483-491(2007) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*02:01). - Ref.60"Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers."
Hadrup S.R., Bakker A.H., Shu C.J., Andersen R.S., van Veluw J., Hombrink P., Castermans E., Thor Straten P., Blank C., Haanen J.B., Heemskerk M.H., Schumacher T.N.
Nat. Methods 6:520-526(2009) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*03:01). - Ref.61"Production of an antigenic peptide by insulin-degrading enzyme."
Parmentier N., Stroobant V., Colau D., de Diesbach P., Morel S., Chapiro J., van Endert P., Van den Eynde B.J.
Nat. Immunol. 11:449-454(2010) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*01:01). - Ref.64"HLA-A*7401-mediated control of HIV viremia is independent of its linkage disequilibrium with HLA-B*5703."
Matthews P.C., Adland E., Listgarten J., Leslie A., Mkhwanazi N., Carlson J.M., Harndahl M., Stryhn A., Payne R.P., Ogwu A., Huang K.H., Frater J., Paioni P., Kloverpris H., Jooste P., Goedhals D., van Vuuren C., Steyn D. , Riddell L., Chen F., Luzzi G., Balachandran T., Ndung'u T., Buus S., Carrington M., Shapiro R., Heckerman D., Goulder P.J.
J. Immunol. 186:5675-5686(2011) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*74:01). - Ref.66"Structure of TCR and antigen complexes at an immunodominant CTL epitope in HIV-1 infection."
Shimizu A., Kawana-Tachikawa A., Yamagata A., Han C., Zhu D., Sato Y., Nakamura H., Koibuchi T., Carlson J., Martin E., Brumme C.J., Shi Y., Gao G.F., Brumme Z.L., Fukai S., Iwamoto A.
Sci. Rep. 3:3097-3097(2013) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*24:02). - Ref.69"A comprehensive analysis of peptides presented by HLA-A1."
Giam K., Ayala-Perez R., Illing P.T., Schittenhelm R.B., Croft N.P., Purcell A.W., Dudek N.L.
Tissue Antigens 85:492-496(2015) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*01:01), SUBCELLULAR LOCATION. - Ref.71"Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome."
Tripathi S.C., Peters H.L., Taguchi A., Katayama H., Wang H., Momin A., Jolly M.K., Celiktas M., Rodriguez-Canales J., Liu H., Behrens C., Wistuba I.I., Ben-Jacob E., Levine H., Molldrem J.J., Hanash S.M., Ostrin E.J.
Proc. Natl. Acad. Sci. U.S.A. 113:E1555-E1564(2016) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*02:01). - Ref.72"Proteasomes generate spliced epitopes by two different mechanisms and as efficiently as non-spliced epitopes."
Ebstein F., Textoris-Taube K., Keller C., Golnik R., Vigneron N., Van den Eynde B.J., Schuler-Thurner B., Schadendorf D., Lorenz F.K., Uckert W., Urban S., Lehmann A., Albrecht-Koepke N., Janek K., Henklein P., Niewienda A., Kloetzel P.M., Mishto M.
Sci. Rep. 6:24032-24032(2016) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*03:01). - Ref.76"The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2."
Madden D.R., Garboczi D.N., Wiley D.C.
Cell 75:693-708(1993) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 25-299 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*02:01), DISULFIDE BOND, DOMAIN. - Ref.81"A structural basis for immunodominant human T cell receptor recognition."
Stewart-Jones G.B.E., McMichael A.J., Bell J.I., Stuart D.I., Jones E.Y.
Nat. Immunol. 4:657-663(2003) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.40 ANGSTROMS) OF 25-300 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, INTERACTION WITH TCR, FUNCTION (ALLELE A*02:01). - Ref.83"The structural dynamics and energetics of an immunodominant T cell receptor are programmed by its Vbeta domain."
Ishizuka J., Stewart-Jones G.B., van der Merwe A., Bell J.I., McMichael A.J., Jones E.Y.
Immunity 28:171-182(2008) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 25-300 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, INTERACTION WITH TCR, FUNCTION (ALLELE A*02:01). - Ref.84"Structural bases for the affinity-driven selection of a public TCR against a dominant human cytomegalovirus epitope."
Gras S., Saulquin X., Reiser J.B., Debeaupuis E., Echasserieau K., Kissenpfennig A., Legoux F., Chouquet A., Le Gorrec M., Machillot P., Neveu B., Thielens N., Malissen B., Bonneville M., Housset D.
J. Immunol. 183:430-437(2009) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 25-298 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*02:01), DOMAIN. - Ref.91"Preexisting CD8+ T-cell immunity to the H7N9 influenza A virus varies across ethnicities."
Quinones-Parra S., Grant E., Loh L., Nguyen T.H., Campbell K.A., Tong S.Y., Miller A., Doherty P.C., Vijaykrishna D., Rossjohn J., Gras S., Kedzierska K.
Proc. Natl. Acad. Sci. U.S.A. 111:1049-1054(2014) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 25-308 (ALLELE A*01:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*01:01), DOMAIN. - Ref.93"Broad TCR repertoire and diverse structural solutions for recognition of an immunodominant CD8+ T cell epitope."
Song I., Gil A., Mishra R., Ghersi D., Selin L.K., Stern L.J.
Nat. Struct. Mol. Biol. 24:395-406(2017) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.06 ANGSTROMS) OF 25-299 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*02:01), DOMAIN, DISULFIDE BOND.
Allele A*01:01: Presents a restricted peptide repertoire including viral epitopes derived from IAV NP/nucleoprotein (CTELKLSDY), IAV PB1/polymerase basic protein 1 (VSDGGPNLY), HAdV-11 capsid L3/hexon protein (LTDLGQNLLY) as well as tumor peptide antigens including MAGE1 (EADPTGHSY), MAGEA3 (EVDPIGHLY) and WT1 (TSEKRPFMCAY), all having in common a canonical motif with a negatively charged Asp or Glu residue at position 3 and a Tyr anchor residue at C-terminal (PubMed:1402688, PubMed:7504010, PubMed:17189421, PubMed:20364150, PubMed:25880248, PubMed:30530481, PubMed:19177349, PubMed:24395804, PubMed:26758806). A number of HLA-A*01:01-restricted peptides carry a post-translational modification with oxidation and N-terminal acetylation being the most frequent (PubMed:25880248). Fails to present highly immunogenic peptides from the EBV latent antigens (PubMed:18779413).10 Publications
Manual assertion based on experiment ini
- Ref.39"A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E."
Traversari C., van der Bruggen P., Luescher I.F., Lurquin C., Chomez P., Van Pel A., De Plaen E., Amar-Costesec A., Boon T.
J. Exp. Med. 176:1453-1457(1992) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*01:01). - Ref.40"HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs."
DiBrino M., Tsuchida T., Turner R.V., Parker K.C., Coligan J.E., Biddison W.E.
J. Immunol. 151:5930-5935(1993) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES A*01:01 AND A*03:01), INTERACTION WITH B2M AND PEPTIDE. - Ref.54"Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1."
Asemissen A.M., Keilholz U., Tenzer S., Mueller M., Walter S., Stevanovic S., Schild H., Letsch A., Thiel E., Rammensee H.G., Scheibenbogen C.
Clin. Cancer Res. 12:7476-7482(2006) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*01:01). - Ref.58"A mechanism for the HLA-A*01-associated risk for EBV+ Hodgkin lymphoma and infectious mononucleosis."
Brennan R.M., Burrows S.R.
Blood 112:2589-2590(2008) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*01:01). - Ref.61"Production of an antigenic peptide by insulin-degrading enzyme."
Parmentier N., Stroobant V., Colau D., de Diesbach P., Morel S., Chapiro J., van Endert P., Van den Eynde B.J.
Nat. Immunol. 11:449-454(2010) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*01:01). - Ref.69"A comprehensive analysis of peptides presented by HLA-A1."
Giam K., Ayala-Perez R., Illing P.T., Schittenhelm R.B., Croft N.P., Purcell A.W., Dudek N.L.
Tissue Antigens 85:492-496(2015) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*01:01), SUBCELLULAR LOCATION. - Ref.73"Measuring Antiviral Capacity of T Cell Responses to Adenovirus."
Keib A., Mei Y.F., Cicin-Sain L., Busch D.H., Dennehy K.M.
J. Immunol. 202:618-624(2019) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*01:01). - Ref.85"Conformational changes within the HLA-A1:MAGE-A1 complex induced by binding of a recombinant antibody fragment with TCR-like specificity."
Kumar P., Vahedi-Faridi A., Saenger W., Ziegler A., Uchanska-Ziegler B.
Protein Sci. 18:37-49(2009) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 25-298 (ALLELE A*01:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*01:01), DOMAIN, DISULFIDE BOND. - Ref.91"Preexisting CD8+ T-cell immunity to the H7N9 influenza A virus varies across ethnicities."
Quinones-Parra S., Grant E., Loh L., Nguyen T.H., Campbell K.A., Tong S.Y., Miller A., Doherty P.C., Vijaykrishna D., Rossjohn J., Gras S., Kedzierska K.
Proc. Natl. Acad. Sci. U.S.A. 111:1049-1054(2014) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 25-308 (ALLELE A*01:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*01:01), DOMAIN. - Ref.92"Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy."
Raman M.C., Rizkallah P.J., Simmons R., Donnellan Z., Dukes J., Bossi G., Le Provost G.S., Todorov P., Baston E., Hickman E., Mahon T., Hassan N., Vuidepot A., Sami M., Cole D.K., Jakobsen B.K.
Sci. Rep. 6:18851-18851(2016) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 25-298 (ALLELE A*01:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*01:01), DOMAIN, DISULFIDE BOND.
Allele A*02:01: A major allele in human populations, presents immunodominant viral epitopes derived from IAV M/matrix protein 1 (GILGFVFTL), HIV-1 env (TLTSCNTSV), HIV-1 gag-pol (ILKEPVHGV), HTLV-1 Tax (LLFGYPVYV), HBV C/core antigen (FLPSDFFPS), HCMV UL83/pp65 (NLVPMVATV) as well as tumor peptide antigens including MAGEA4 (GVYDGREHTV), WT1 (RMFPNAPYL) and CTAG1A/NY-ESO-1 (SLLMWITQC), all having in common hydrophobic amino acids at position 2 and at C-terminal anchors.17 Publications
Manual assertion based on experiment ini
- Ref.38"Polymorphism in the alpha 3 domain of HLA-A molecules affects binding to CD8."
Salter R.D., Norment A.M., Chen B.P., Clayberger C., Krensky A.M., Littman D.R., Parham P.
Nature 338:345-347(1989) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES A*02:01 AND A*68:01), INTERACTION WITH CD8A, DOMAIN, CHARACTERIZATION OF VARIANT VAL-269. - Ref.43"Point mutations in the alpha 2 domain of HLA-A2.1 define a functionally relevant interaction with TAP."
Lewis J.W., Neisig A., Neefjes J., Elliott T.
Curr. Biol. 6:873-883(1996) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*02:01), MUTAGENESIS OF SER-156 AND THR-158, DOMAIN, INTERACTION WITH B2M, INTERACTION WITH TAP1-TAP2 COMPLEX, SUBCELLULAR LOCATION. - Ref.44"A point mutation in HLA-A*0201 results in failure to bind the TAP complex and to present virus-derived peptides to CTL."
Peace-Brewer A.L., Tussey L.G., Matsui M., Li G., Quinn D.G., Frelinger J.A.
Immunity 4:505-514(1996) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*02:01), INTERACTION WITH TAP1-TAP2 COMPLEX, MUTAGENESIS OF THR-158. - Ref.51"Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations."
Nagata Y., Ono S., Matsuo M., Gnjatic S., Valmori D., Ritter G., Garrett W., Old L.J., Mellman I.
Proc. Natl. Acad. Sci. U.S.A. 99:10629-10634(2002) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*02:01). - Ref.56"Role of immunoproteasome catalytic subunits in the immune response to hepatitis B virus."
Robek M.D., Garcia M.L., Boyd B.S., Chisari F.V.
J. Virol. 81:483-491(2007) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*02:01). - Ref.71"Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome."
Tripathi S.C., Peters H.L., Taguchi A., Katayama H., Wang H., Momin A., Jolly M.K., Celiktas M., Rodriguez-Canales J., Liu H., Behrens C., Wistuba I.I., Ben-Jacob E., Levine H., Molldrem J.J., Hanash S.M., Ostrin E.J.
Proc. Natl. Acad. Sci. U.S.A. 113:E1555-E1564(2016) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*02:01). - Ref.76"The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2."
Madden D.R., Garboczi D.N., Wiley D.C.
Cell 75:693-708(1993) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 25-299 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*02:01), DISULFIDE BOND, DOMAIN. - Ref.77"Three-dimensional structure of a peptide extending from one end of a class I MHC binding site."
Collins E.J., Garboczi D.N., Wiley D.C.
Nature 371:626-629(1994) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 25-299 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*02:01). - Ref.78"Structure of the complex between human T-cell receptor, viral peptide and HLA-A2."
Garboczi D.N., Ghosh P., Utz U., Fan Q.R., Biddison W.E., Wiley D.C.
Nature 384:134-141(1996) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 25-299 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*02:01), DOMAIN. - Ref.79"Crystal structure of the complex between human CD8alpha(alpha) and HLA-A2."
Gao G.F., Tormo J., Gerth U.C., Wyer J.R., McMichael A.J., Stuart D.I., Bell J.I., Jones E.Y., Jakobsen B.K.
Nature 387:630-634(1997) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 25-300 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, INTERACTION WITH CD8A, FUNCTION (ALLELE A*02:01). - Ref.80"High-resolution structure of HLA-A*0201 in complex with a tumour-specific antigenic peptide encoded by the MAGE-A4 gene."
Hillig R.C., Coulie P.G., Stroobant V., Saenger W., Ziegler A., Hulsmeyer M.
J. Mol. Biol. 310:1167-1176(2001) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.40 ANGSTROMS) OF 25-299 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*02:01). - Ref.81"A structural basis for immunodominant human T cell receptor recognition."
Stewart-Jones G.B.E., McMichael A.J., Bell J.I., Stuart D.I., Jones E.Y.
Nat. Immunol. 4:657-663(2003) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.40 ANGSTROMS) OF 25-300 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, INTERACTION WITH TCR, FUNCTION (ALLELE A*02:01). - Ref.83"The structural dynamics and energetics of an immunodominant T cell receptor are programmed by its Vbeta domain."
Ishizuka J., Stewart-Jones G.B., van der Merwe A., Bell J.I., McMichael A.J., Jones E.Y.
Immunity 28:171-182(2008) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 25-300 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, INTERACTION WITH TCR, FUNCTION (ALLELE A*02:01). - Ref.84"Structural bases for the affinity-driven selection of a public TCR against a dominant human cytomegalovirus epitope."
Gras S., Saulquin X., Reiser J.B., Debeaupuis E., Echasserieau K., Kissenpfennig A., Legoux F., Chouquet A., Le Gorrec M., Machillot P., Neveu B., Thielens N., Malissen B., Bonneville M., Housset D.
J. Immunol. 183:430-437(2009) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 25-298 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*02:01), DOMAIN. - Ref.87"Structures of native and affinity-enhanced WT1 epitopes bound to HLA-A*0201: implications for WT1-based cancer therapeutics."
Borbulevych O.Y., Do P., Baker B.M.
Mol. Immunol. 47:2519-2524(2010) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.89 ANGSTROMS) OF 25-299 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*02:01), DOMAIN. - Ref.90"Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes."
Bulek A.M., Cole D.K., Skowera A., Dolton G., Gras S., Madura F., Fuller A., Miles J.J., Gostick E., Price D.A., Drijfhout J.W., Knight R.R., Huang G.C., Lissin N., Molloy P.E., Wooldridge L., Jakobsen B.K., Rossjohn J. , Peakman M., Rizkallah P.J., Sewell A.K.
Nat. Immunol. 13:283-289(2012) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.67 ANGSTROMS) OF 25-300 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, INTERACTION WITH TCR, FUNCTION (ALLELE A*02:01), DOMAIN, INDUCTION BY CYTOKINES, INVOLVEMENT IN IDDM (ALLELE A*02:01). - Ref.93"Broad TCR repertoire and diverse structural solutions for recognition of an immunodominant CD8+ T cell epitope."
Song I., Gil A., Mishra R., Ghersi D., Selin L.K., Stern L.J.
Nat. Struct. Mol. Biol. 24:395-406(2017) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.06 ANGSTROMS) OF 25-299 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*02:01), DOMAIN, DISULFIDE BOND.
Allele A*03:01: Presents viral epitopes derived from IAV NP (ILRGSVAHK), HIV-1 nef (QVPLRPMTYK), HIV-1 gag-pol (AIFQSSMTK) as well as tumor peptide antigens including PMEL (LIYRRRLMK), NODAL (HAYIQSLLK), TRP-2 (RMYNMVPFF), all having in common hydrophobic amino acids at position 2 and Lys or Arg anchor residues at C-terminal (PubMed:7504010, PubMed:7679507, PubMed:9862734, PubMed:19543285, PubMed:21943705, PubMed:2456340). May also display spliced peptides resulting from the ligation of two separate proteasomal cleavage products that are not contiguous in the parental protein (PubMed:27049119).7 Publications
Manual assertion based on experiment ini
- Ref.37"Analysis of the molecular basis of HLA-A3 recognition by cytotoxic T cells using defined mutants of the HLA-A3 molecule."
Jelachich M.L., Cowan E.P., Turner R.V., Coligan J.E., Biddison W.E.
J. Immunol. 141:1108-1113(1988) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*03:01), CHARACTERIZATION OF VARIANT VAL-176. - Ref.40"HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs."
DiBrino M., Tsuchida T., Turner R.V., Parker K.C., Coligan J.E., Biddison W.E.
J. Immunol. 151:5930-5935(1993) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES A*01:01 AND A*03:01), INTERACTION WITH B2M AND PEPTIDE. - Ref.41"Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides."
DiBrino M., Parker K.C., Shiloach J., Knierman M., Lukszo J., Turner R.V., Biddison W.E., Coligan J.E.
Proc. Natl. Acad. Sci. U.S.A. 90:1508-1512(1993) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*03:01), INTERACTION WITH B2M AND PEPTIDE. - Ref.47"Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles."
Kawakami Y., Robbins P.F., Wang X., Tupesis J.P., Parkhurst M.R., Kang X., Sakaguchi K., Appella E., Rosenberg S.A.
J. Immunol. 161:6985-6992(1998) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*03:01). - Ref.60"Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers."
Hadrup S.R., Bakker A.H., Shu C.J., Andersen R.S., van Veluw J., Hombrink P., Castermans E., Thor Straten P., Blank C., Haanen J.B., Heemskerk M.H., Schumacher T.N.
Nat. Methods 6:520-526(2009) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*03:01). - Ref.72"Proteasomes generate spliced epitopes by two different mechanisms and as efficiently as non-spliced epitopes."
Ebstein F., Textoris-Taube K., Keller C., Golnik R., Vigneron N., Van den Eynde B.J., Schuler-Thurner B., Schadendorf D., Lorenz F.K., Uckert W., Urban S., Lehmann A., Albrecht-Koepke N., Janek K., Henklein P., Niewienda A., Kloetzel P.M., Mishto M.
Sci. Rep. 6:24032-24032(2016) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*03:01). - Ref.89"Structural basis of cross-allele presentation by HLA-A*0301 and HLA-A*1101 revealed by two HIV-derived peptide complexes."
Zhang S., Liu J., Cheng H., Tan S., Qi J., Yan J., Gao G.F.
Mol. Immunol. 49:395-401(2011) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 25-298 (ALLELE A*03:01) IN COMPLEX WITH B2M AND PEPTIDE, DISULFIDE BOND, DOMAIN, FUNCTION (ALLELE A*03:01).
Allele A*11:01: Presents several immunodominant epitopes derived from HIV-1 gag-pol and HHV-4 EBNA4, containing the peptide motif with Val, Ile, Thr, Leu, Tyr or Phe at position 2 and Lys anchor residue at C-terminal. Important in the control of HIV-1, EBV and HBV infections.1 Publication
Manual assertion based on experiment ini
- Ref.48"HLA-A*1101-restricted cytotoxic T lymphocyte recognition of HIV-1 Pol protein."
Fukada K., Chujoh Y., Tomiyama H., Miwa K., Kaneko Y., Oka S., Takiguchi M.
AIDS 13:1413-1414(1999) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*11:01).
Allele A*23:01: Interacts with natural killer (NK) cell receptor KIR3DL1 and may contribute to functional maturation of NK cells and self-nonself discrimination during innate immune response.1 Publication
Manual assertion based on experiment ini
- Ref.55"Cutting Edge: Allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B."
Thananchai H., Gillespie G., Martin M.P., Bashirova A., Yawata N., Yawata M., Easterbrook P., McVicar D.W., Maenaka K., Parham P., Carrington M., Dong T., Rowland-Jones S.
J. Immunol. 178:33-37(2007) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES A*23:01; A*24:02 AND A*32:01), INTERACTION WITH KIR3DL1.
Allele A*24:02: Presents viral epitopes derived from HIV-1 nef (RYPLTFGWCF), EBV lytic- and latent-cycle antigens BRLF1 (TYPVLEEMF), BMLF1 (DYNFVKQLF) and LMP2 (IYVLVMLVL), SARS-CoV nucleocapsid/N (QFKDNVILL), as well as tumor peptide antigens including PRAME (LYVDSLFFL), all sharing a common signature motif, namely an aromatic residue Tyr or Phe at position 2 and a nonhydrophobic anchor residue Phe, Leu or Iso at C-terminal (PubMed:9047241, PubMed:12393434, PubMed:24192765, PubMed:20844028). Interacts with natural killer (NK) cell receptor KIR3DL1 and may contribute to functional maturation of NK cells and self-nonself discrimination during innate immune response (PubMed:17182537, PubMed:18502829).6 Publications
Manual assertion based on experiment ini
- Ref.46"Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor."
Ikeda H., Lethe B.G., Lehmann F., van Baren N., Baurain J.-F., de Smet C., Chambost H., Vitale M., Moretta A., Boon T., Coulie P.G.
Immunity 6:199-208(1997) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*24:02). - Ref.52"Tetramer-assisted identification and characterization of epitopes recognized by HLA A*2402-restricted Epstein-Barr virus-specific CD8+ T cells."
Kuzushima K., Hayashi N., Kudoh A., Akatsuka Y., Tsujimura K., Morishima Y., Tsurumi T.
Blood 101:1460-1468(2003) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*24:02). - Ref.55"Cutting Edge: Allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B."
Thananchai H., Gillespie G., Martin M.P., Bashirova A., Yawata N., Yawata M., Easterbrook P., McVicar D.W., Maenaka K., Parham P., Carrington M., Dong T., Rowland-Jones S.
J. Immunol. 178:33-37(2007) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES A*23:01; A*24:02 AND A*32:01), INTERACTION WITH KIR3DL1. - Ref.57"Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1."
Stern M., Ruggeri L., Capanni M., Mancusi A., Velardi A.
Blood 112:708-710(2008) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*24:02), INTERACTION WITH KIR3DL1. - Ref.66"Structure of TCR and antigen complexes at an immunodominant CTL epitope in HIV-1 infection."
Shimizu A., Kawana-Tachikawa A., Yamagata A., Han C., Zhu D., Sato Y., Nakamura H., Koibuchi T., Carlson J., Martin E., Brumme C.J., Shi Y., Gao G.F., Brumme Z.L., Fukai S., Iwamoto A.
Sci. Rep. 3:3097-3097(2013) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*24:02). - Ref.86"Novel immunodominant peptide presentation strategy: a featured HLA-A*2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein."
Liu J., Wu P., Gao F., Qi J., Kawana-Tachikawa A., Xie J., Vavricka C.J., Iwamoto A., Li T., Gao G.F.
J. Virol. 84:11849-11857(2010) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 25-298 (ALLELE A*24:02) IN COMPLEX WITH B2M AND WITH SARS NUCLEOCAPSID PEPTIDE, DISULFIDE BONDS, FUNCTION (ALLELE A*24:02), DOMAIN.
Allele A*26:01: Presents several epitopes derived from HIV-1 gag-pol (EVIPMFSAL, ETKLGKAGY) and env (LVSDGGPNLY), carrying as anchor residues preferentially Glu at position 1, Val or Thr at position 2 and Tyr at C-terminal.1 Publication
Manual assertion based on experiment ini
- Ref.53"Identification and characterization of HIV-1-specific CD8+ T cell epitopes presented by HLA-A*2601."
Satoh M., Takamiya Y., Oka S., Tokunaga K., Takiguchi M.
Vaccine 23:3783-3790(2005) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*26:01).
Allele A*29:02: Presents peptides having a common motif, namely a Glu residue at position 2 and Tyr or Leu anchor residues at C-terminal.1 Publication
Manual assertion based on experiment ini
- Ref.45"Definition of the HLA-A29 peptide ligand motif allows prediction of potential T-cell epitopes from the retinal soluble antigen, a candidate autoantigen in birdshot retinopathy."
Boisgerault F., Khalil I., Tieng V., Connan F., Tabary T., Cohen J.H., Choppin J., Charron D., Toubert A.
Proc. Natl. Acad. Sci. U.S.A. 93:3466-3470(1996) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*29:02).
Allele A*32:01: Interacts with natural killer (NK) cell receptor KIR3DL1 and may contribute to functional maturation of NK cells and self-nonself discrimination during innate immune response.1 Publication
Manual assertion based on experiment ini
- Ref.55"Cutting Edge: Allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B."
Thananchai H., Gillespie G., Martin M.P., Bashirova A., Yawata N., Yawata M., Easterbrook P., McVicar D.W., Maenaka K., Parham P., Carrington M., Dong T., Rowland-Jones S.
J. Immunol. 178:33-37(2007) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES A*23:01; A*24:02 AND A*32:01), INTERACTION WITH KIR3DL1.
Allele A*68:01: Presents viral epitopes derived from IAV NP (KTGGPIYKR) and HIV-1 tat (ITKGLGISYGR), having a common signature motif namely, Val or Thr at position 2 and positively charged residues Arg or Lys at C-terminal anchor.3 Publications
Manual assertion based on experiment ini
- Ref.38"Polymorphism in the alpha 3 domain of HLA-A molecules affects binding to CD8."
Salter R.D., Norment A.M., Chen B.P., Clayberger C., Krensky A.M., Littman D.R., Parham P.
Nature 338:345-347(1989) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES A*02:01 AND A*68:01), INTERACTION WITH CD8A, DOMAIN, CHARACTERIZATION OF VARIANT VAL-269. - Ref.74"Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle."
Guo H.-C., Jardetzky T.S., Garrett T.P.J., Lane W.S., Strominger J.L., Wiley D.C.
Nature 360:364-366(1992) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 25-294 (ALLELE A*68:01), FUNCTION (ALLELE A*68:01). - Ref.75"Atomic structure of a human MHC molecule presenting an influenza virus peptide."
Silver M.L., Guo H.-C., Strominger J.L., Wiley D.C.
Nature 360:367-369(1992) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 25-294 (ALLELE A*68:01), FUNCTION (ALLELE A*68:01).
Allele A*74:01: Presents immunodominant HIV-1 epitopes derived from gag-pol (GQMVHQAISPR, QIYPGIKVR) and rev (RQIHSISER), carrying an aliphatic residue at position 2 and Arg anchor residue at C-terminal. May contribute to viral load control in chronic HIV-1 infection.1 Publication
Manual assertion based on experiment ini
- Ref.64"HLA-A*7401-mediated control of HIV viremia is independent of its linkage disequilibrium with HLA-B*5703."
Matthews P.C., Adland E., Listgarten J., Leslie A., Mkhwanazi N., Carlson J.M., Harndahl M., Stryhn A., Payne R.P., Ogwu A., Huang K.H., Frater J., Paioni P., Kloverpris H., Jooste P., Goedhals D., van Vuuren C., Steyn D. , Riddell L., Chen F., Luzzi G., Balachandran T., Ndung'u T., Buus S., Carrington M., Shapiro R., Heckerman D., Goulder P.J.
J. Immunol. 186:5675-5686(2011) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*74:01).
Sites
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| <p>This subsection of the <a href="http://www.uniprot.org/help/function_section">Function</a> section describes the interaction between a single amino acid and another chemical entity. Priority is given to the annotation of physiological ligands.<p><a href='/help/binding' target='_top'>More...</a></p>Binding sitei | 31 | Pathogen-derived peptide antigen1 Publication Manual assertion based on experiment ini
| 1 | |
| Binding sitei | 97 | Pathogen-derived peptide antigen1 Publication Manual assertion based on experiment ini
| 1 | |
| Binding sitei | 108 | Pathogen-derived peptide antigen1 Publication Manual assertion based on experiment ini
| 1 | |
| Binding sitei | 140 | Self-peptide antigen1 Publication Manual assertion based on experiment ini
| 1 | |
| Binding sitei | 167 | Pathogen-derived peptide antigen1 Publication Manual assertion based on experiment ini
| 1 | |
| Binding sitei | 170 | Pathogen-derived peptide antigen1 Publication Manual assertion based on experiment ini
| 1 | |
| Binding sitei | 183 | Self- and pathogen-derived peptide antigen2 Publications Manual assertion based on experiment ini
| 1 | |
| Binding sitei | 195 | Pathogen-derived peptide antigen1 Publication Manual assertion based on experiment ini
| 1 |
<p>The <a href="http://www.geneontology.org/">Gene Ontology (GO)</a> project provides a set of hierarchical controlled vocabulary split into 3 categories:<p><a href='/help/gene_ontology' target='_top'>More...</a></p>GO - Molecular functioni
- beta-2-microglobulin binding Source: UniProtKB
- peptide antigen binding Source: UniProtKB
<p>Inferred from Direct Assay</p>
<p>Used to indicate a direct assay for the function, process or component indicated by the GO term.</p>
<p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ida">GO evidence code guide</a></p>
Inferred from direct assayi
- Ref.40"HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs."
DiBrino M., Tsuchida T., Turner R.V., Parker K.C., Coligan J.E., Biddison W.E.
J. Immunol. 151:5930-5935(1993) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES A*01:01 AND A*03:01), INTERACTION WITH B2M AND PEPTIDE.
- TAP binding Source: UniProtKBInferred from direct assayi
- "Allele-specific differences in the interaction of MHC class I molecules with transporters associated with antigen processing."
Neisig A., Wubbolts R., Zang X., Melief C., Neefjes J.
J. Immunol. 156:3196-3206(1996) [PubMed] [Europe PMC] [Abstract]
GO - Biological processi
- antigen processing and presentation of exogenous peptide antigen via MHC class I Source: UniProtKBInferred from direct assayi
- Ref.40"HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs."
DiBrino M., Tsuchida T., Turner R.V., Parker K.C., Coligan J.E., Biddison W.E.
J. Immunol. 151:5930-5935(1993) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES A*01:01 AND A*03:01), INTERACTION WITH B2M AND PEPTIDE.
- antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent Source: Reactome
- antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent Source: Reactome
- antigen processing and presentation of peptide antigen via MHC class I Source: Reactome
- CD8-positive, alpha-beta T cell activation Source: UniProtKBInferred from direct assayi
- Ref.40"HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs."
DiBrino M., Tsuchida T., Turner R.V., Parker K.C., Coligan J.E., Biddison W.E.
J. Immunol. 151:5930-5935(1993) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES A*01:01 AND A*03:01), INTERACTION WITH B2M AND PEPTIDE.
- immune response Source: UniProtKB
<p>Non-traceable Author Statement</p>
<p>Used for statements in the abstract, introduction or discussion of a paper that cannot be traced back to another publication.</p>
<p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#nas">GO evidence code guide</a></p>
Non-traceable author statementi
- Ref.19"Complete nucleotide sequence of a functional class I HLA gene, HLA-A3: implications for the evolution of HLA genes."
Strachan T., Sodoyer R., Damotte M., Jordan B.R.
EMBO J. 3:887-894(1984) [PubMed] [Europe PMC] [Abstract]Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*03:01).
- interferon-gamma-mediated signaling pathway Source: Reactome
- protein ubiquitination Source: Reactome
- regulation of immune response Source: Reactome
- T cell mediated cytotoxicity Source: UniProtKBInferred from direct assayi
- Ref.40"HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs."
DiBrino M., Tsuchida T., Turner R.V., Parker K.C., Coligan J.E., Biddison W.E.
J. Immunol. 151:5930-5935(1993) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES A*01:01 AND A*03:01), INTERACTION WITH B2M AND PEPTIDE.
- type I interferon signaling pathway Source: Reactome
<p>UniProtKB Keywords constitute a <a href="http://www.uniprot.org/keywords">controlled vocabulary</a> with a hierarchical structure. Keywords summarise the content of a UniProtKB entry and facilitate the search for proteins of interest.<p><a href='/help/keywords' target='_top'>More...</a></p>Keywordsi
| Biological process | Adaptive immunity, Host-virus interaction, Immunity, Innate immunity |
Enzyme and pathway databases
Reactome - a knowledgebase of biological pathways and processes More...Reactomei | R-HSA-1236974 ER-Phagosome pathway R-HSA-1236977 Endosomal/Vacuolar pathway R-HSA-198933 Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell R-HSA-877300 Interferon gamma signaling R-HSA-8866654 E3 ubiquitin ligases ubiquitinate target proteins R-HSA-909733 Interferon alpha/beta signaling R-HSA-983170 Antigen Presentation: Folding, assembly and peptide loading of class I MHC |
SIGNOR Signaling Network Open Resource More...SIGNORi | P04439 |
<p>This section provides information about the protein and gene name(s) and synonym(s) and about the organism that is the source of the protein sequence.<p><a href='/help/names_and_taxonomy_section' target='_top'>More...</a></p>Names & Taxonomyi
| <p>This subsection of the <a href="http://www.uniprot.org/help/names_and_taxonomy_section">Names and taxonomy</a> section provides an exhaustive list of all names of the protein, from commonly used to obsolete, to allow unambiguous identification of a protein.<p><a href='/help/protein_names' target='_top'>More...</a></p>Protein namesi | Recommended name: HLA class I histocompatibility antigen, A alpha chainAlternative name(s): Human leukocyte antigen A Short name: HLA-A |
| <p>This subsection of the <a href="http://www.uniprot.org/help/names_and_taxonomy_section">Names and taxonomy</a> section indicates the name(s) of the gene(s) that code for the protein sequence(s) described in the entry. Four distinct tokens exist: ‘Name’, ‘Synonyms’, ‘Ordered locus names’ and ‘ORF names’.<p><a href='/help/gene_name' target='_top'>More...</a></p>Gene namesi | |
| <p>This subsection of the <a href="http://www.uniprot.org/help/names_and_taxonomy_section">Names and taxonomy</a> section provides information on the name(s) of the organism that is the source of the protein sequence.<p><a href='/help/organism-name' target='_top'>More...</a></p>Organismi | Homo sapiens (Human) |
| <p>This subsection of the <a href="http://www.uniprot.org/help/names_and_taxonomy_section">Names and taxonomy</a> section shows the unique identifier assigned by the NCBI to the source organism of the protein. This is known as the ‘taxonomic identifier’ or ‘taxid’.<p><a href='/help/taxonomic_identifier' target='_top'>More...</a></p>Taxonomic identifieri | 9606 [NCBI] |
| <p>This subsection of the <a href="http://www.uniprot.org/help/names_and_taxonomy_section">Names and taxonomy</a> section contains the taxonomic hierarchical classification lineage of the source organism. It lists the nodes as they appear top-down in the taxonomic tree, with the more general grouping listed first.<p><a href='/help/taxonomic_lineage' target='_top'>More...</a></p>Taxonomic lineagei | cellular organisms › Eukaryota › Opisthokonta › Metazoa › Eumetazoa › Bilateria › Deuterostomia › Chordata › Craniata › Vertebrata › Gnathostomata › Teleostomi › Euteleostomi › Sarcopterygii › Dipnotetrapodomorpha › Tetrapoda › Amniota › Mammalia › Theria › Eutheria › Boreoeutheria › Euarchontoglires › Primates › Haplorrhini › Simiiformes › Catarrhini › Hominoidea › Hominidae › Homininae › Homo |
| <p>This subsection of the <a href="http://www.uniprot.org/help/names_and_taxonomy_section">Names and taxonomy</a> section is present for entries that are part of a <a href="http://www.uniprot.org/proteomes">proteome</a>, i.e. of a set of proteins thought to be expressed by organisms whose genomes have been completely sequenced.<p><a href='/help/proteomes_manual' target='_top'>More...</a></p>Proteomesi |
|
Organism-specific databases
Human Gene Nomenclature Database More...HGNCi | HGNC:4931 HLA-A |
Online Mendelian Inheritance in Man (OMIM) More...MIMi | 142800 gene |
<p>This section provides information on the location and the topology of the mature protein in the cell.<p><a href='/help/subcellular_location_section' target='_top'>More...</a></p>Subcellular locationi
Endoplasmic reticulum
- Endoplasmic reticulum membrane 1 Publication
<p>Manually curated information which has been inferred by a curator based on his/her scientific knowledge or on the scientific content of an article.</p> <p><a href="/manual/evidences#ECO:0000305">More...</a></p> Manual assertion inferred by curator fromi
- Ref.43"Point mutations in the alpha 2 domain of HLA-A2.1 define a functionally relevant interaction with TAP."
Lewis J.W., Neisig A., Neefjes J., Elliott T.
Curr. Biol. 6:873-883(1996) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*02:01), MUTAGENESIS OF SER-156 AND THR-158, DOMAIN, INTERACTION WITH B2M, INTERACTION WITH TAP1-TAP2 COMPLEX, SUBCELLULAR LOCATION.
- Endoplasmic reticulum membrane 1 Publication
Plasma membrane
- Cell membrane 3 Publications
Manual assertion based on experiment ini
- Ref.43"Point mutations in the alpha 2 domain of HLA-A2.1 define a functionally relevant interaction with TAP."
Lewis J.W., Neisig A., Neefjes J., Elliott T.
Curr. Biol. 6:873-883(1996) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*02:01), MUTAGENESIS OF SER-156 AND THR-158, DOMAIN, INTERACTION WITH B2M, INTERACTION WITH TAP1-TAP2 COMPLEX, SUBCELLULAR LOCATION. - Ref.63"Distinct functions for the glycans of tapasin and heavy chains in the assembly of MHC class I molecules."
Rizvi S.M., Del Cid N., Lybarger L., Raghavan M.
J. Immunol. 186:2309-2320(2011) [PubMed] [Europe PMC] [Abstract]Cited for: INDUCTION BY IFNG, GLYCOSYLATION AT ASN-110, MUTAGENESIS OF ASN-110, SUBCELLULAR LOCATION, INTERACTION WITH TAPBP. - Ref.69"A comprehensive analysis of peptides presented by HLA-A1."
Giam K., Ayala-Perez R., Illing P.T., Schittenhelm R.B., Croft N.P., Purcell A.W., Dudek N.L.
Tissue Antigens 85:492-496(2015) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*01:01), SUBCELLULAR LOCATION.
- Cell membrane 3 Publications
Endoplasmic reticulum
- endoplasmic reticulum Source: UniProtKB
- endoplasmic reticulum membrane Source: Reactome
- integral component of lumenal side of endoplasmic reticulum membrane Source: Reactome
Endosome
- early endosome membrane Source: Reactome
- recycling endosome membrane Source: Reactome
Golgi apparatus
- Golgi apparatus Source: UniProtKB
- Golgi membrane Source: Reactome
Plasma Membrane
- integral component of plasma membrane Source: UniProtKBNon-traceable author statementi
- Ref.19"Complete nucleotide sequence of a functional class I HLA gene, HLA-A3: implications for the evolution of HLA genes."
Strachan T., Sodoyer R., Damotte M., Jordan B.R.
EMBO J. 3:887-894(1984) [PubMed] [Europe PMC] [Abstract]Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*03:01).
- MHC class I protein complex Source: UniProtKB
- plasma membrane Source: Reactome
- integral component of plasma membrane Source: UniProtKBNon-traceable author statementi
Other locations
- cell surface Source: UniProtKB
- ER to Golgi transport vesicle membrane Source: Reactome
- membrane Source: UniProtKBInferred from high throughput direct assayi
- "Defining the membrane proteome of NK cells."
Ghosh D., Lippert D., Krokhin O., Cortens J.P., Wilkins J.A.
J Mass Spectrom 45:1-25(2010) [PubMed] [Europe PMC] [Abstract]
- phagocytic vesicle membrane Source: Reactome
Topology
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| <p>This subsection of the <a href="http://www.uniprot.org/help/subcellular_location_section">'Subcellular location'</a> section describes the subcellular compartment where each non-membrane region of a membrane-spanning protein is found.<p><a href='/help/topo_dom' target='_top'>More...</a></p>Topological domaini | 25 – 308 | ExtracellularSequence analysisAdd BLAST | 284 | |
| <p>This subsection of the <a href="http://www.uniprot.org/help/subcellular_location_section">'Subcellular location'</a> section describes the extent of a membrane-spanning region of the protein. It denotes the presence of both alpha-helical transmembrane regions and the membrane spanning regions of beta-barrel transmembrane proteins.<p><a href='/help/transmem' target='_top'>More...</a></p>Transmembranei | 309 – 332 | HelicalSequence analysisAdd BLAST | 24 | |
| Topological domaini | 333 – 365 | CytoplasmicSequence analysisAdd BLAST | 33 |
Keywords - Cellular componenti
Cell membrane, Endoplasmic reticulum, Membrane, MHC I<p>This section provides information on the disease(s) and phenotype(s) associated with a protein.<p><a href='/help/pathology_and_biotech_section' target='_top'>More...</a></p>Pathology & Biotechi
<p>This subsection of the ‘Pathology and Biotech’ section provides information on the disease(s) associated with genetic variations in a given protein. The information is extracted from the scientific literature and diseases that are also described in the <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim">OMIM</a> database are represented with a <a href="http://www.uniprot.org/diseases">controlled vocabulary</a> in the following way:<p><a href='/help/involvement_in_disease' target='_top'>More...</a></p>Involvement in diseasei
Alleles A*02:01 and A*24:02 are associated with increased susceptibility to diabetes mellitus, insulin-dependent (IDDM) [MIM:222100] (PubMed:22245737, PubMed:18802479, PubMed:16731854, PubMed:22522618). In a glucose-dependent way, allele A*02:01 may aberrantly present the signal peptide of preproinsulin (ALWGPDPAAA) on the surface of pancreatic beta cells to autoreactive CD8-positive T cells, potentially driving T-cell mediated cytotoxicity in pancreatic islets (PubMed:22245737, PubMed:18802479). Allele A*24:02 may present the signal peptide of preproinsulin (LWMRLLPLL) and contribute to acute pancreatic beta-cell destruction and early onset of IDDM (PubMed:16731854, PubMed:22522618).4 Publications
Manual assertion based on experiment ini
- Ref.90"Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes."
Bulek A.M., Cole D.K., Skowera A., Dolton G., Gras S., Madura F., Fuller A., Miles J.J., Gostick E., Price D.A., Drijfhout J.W., Knight R.R., Huang G.C., Lissin N., Molloy P.E., Wooldridge L., Jakobsen B.K., Rossjohn J. , Peakman M., Rizkallah P.J., Sewell A.K.
Nat. Immunol. 13:283-289(2012) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.67 ANGSTROMS) OF 25-300 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, INTERACTION WITH TCR, FUNCTION (ALLELE A*02:01), DOMAIN, INDUCTION BY CYTOKINES, INVOLVEMENT IN IDDM (ALLELE A*02:01). - Ref.96"Combination of HLA-A24, -DQA1*03, and -DR9 contributes to acute-onset and early complete beta-cell destruction in type 1 diabetes: longitudinal study of residual beta-cell function."
Nakanishi K., Inoko H.
Diabetes 55:1862-1868(2006) [PubMed] [Europe PMC] [Abstract]Cited for: ASSOCIATION OF ALLELE A*24:02 WITH IDDM. - Ref.97"CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope."
Skowera A., Ellis R.J., Varela-Calvino R., Arif S., Huang G.C., Van-Krinks C., Zaremba A., Rackham C., Allen J.S., Tree T.I., Zhao M., Dayan C.M., Sewell A.K., Unger W.W., Unger W., Drijfhout J.W., Ossendorp F., Roep B.O., Peakman M.
J. Clin. Invest. 118:3390-3402(2008) [PubMed] [Europe PMC] [Abstract]Cited for: ASSOCIATION OF ALLELE A*02:01 WITH IDDM. - Ref.99"Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill beta-cells."
Kronenberg D., Knight R.R., Estorninho M., Ellis R.J., Kester M.G., de Ru A., Eichmann M., Huang G.C., Powrie J., Dayan C.M., Skowera A., van Veelen P.A., Peakman M.
Diabetes 61:1752-1759(2012) [PubMed] [Europe PMC] [Abstract]Cited for: ASSOCIATION OF ALLELE A*24:02 WITH IDDM.
Allele A*03:01 is associated with increased susceptibility to multiple sclerosis (MS), an autoimmune disease of the central nervous system [MIM:126200] (PubMed:10746785). May contribute to the initiation phase of the disease by presenting myelin PLP1 self-peptide (KLIETYFSK) to autoreactive CD8-positive T cells capable of initiating the first autoimmune attacks (PubMed:18953350).2 Publications
Manual assertion based on experiment ini
- Ref.95"Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease."
Fogdell-Hahn A., Ligers A., Groenning M., Hillert J., Olerup O.
Tissue Antigens 55:140-148(2000) [PubMed] [Europe PMC] [Abstract]Cited for: ASSOCIATION OF ALLELE A*03:01 WITH MULTIPLE SCLEROSIS. - Ref.98"Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis."
Friese M.A., Jakobsen K.B., Friis L., Etzensperger R., Craner M.J., McMahon R.M., Jensen L.T., Huygelen V., Jones E.Y., Bell J.I., Fugger L.
Nat. Med. 14:1227-1235(2008) [PubMed] [Europe PMC] [Abstract]Cited for: ASSOCIATION OF ALLELE A*03:01 WITH MULTIPLE SCLEROSIS.
Allele A*26:01 is associated with increased susceptibility to Behcet's disease (BD) [MIM:109650] in the Northeast Asian population. Especially in the HLA-B*51-negative BD populations, HLA-A*26 is significantly associated with the onset of BD.1 Publication
Manual assertion based on experiment ini
- Ref.101"The association analysis between HLA-A*26 and Behcet's disease."
Nakamura J., Meguro A., Ishii G., Mihara T., Takeuchi M., Mizuki Y., Yuda K., Yamane T., Kawagoe T., Ota M., Mizuki N.
Sci. Rep. 9:4426-4426(2019) [PubMed] [Europe PMC] [Abstract]Cited for: ASSOCIATION OF ALLELE A*26:01 WITH BEHCET'S DISEASE.
Allele A*29:02 is associated with increased susceptibility to birdshot chorioretinopathy (BSCR) [MIM:605808]. May aberrantly present retinal autoantigens and induce autoimmune uveitis.1 Publication
Manual assertion based on experiment ini
- Ref.94"HLA-A29.2 subtype associated with birdshot retinochoroidopathy."
LeHoang P., Ozdemir N., Benhamou A., Tabary T., Edelson C., Betuel H., Semiglia R., Cohen J.H.
Am. J. Ophthalmol. 113:33-35(1992) [PubMed] [Europe PMC] [Abstract]Cited for: ASSOCIATION OF ALLELE A*29:02 WITH BIRDSHOT CHORIORETINOPATHY.
Allele A*31:01 is associated with carbamazepine-induced hypersensitivity reactions among subjects of Northern European ancestry [MIM:608579].1 Publication
Manual assertion based on experiment ini
- Ref.100"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans."
McCormack M., Alfirevic A., Bourgeois S., Farrell J.J., Kasperaviciute D., Carrington M., Sills G.J., Marson T., Jia X., de Bakker P.I., Chinthapalli K., Molokhia M., Johnson M.R., O'Connor G.D., Chaila E., Alhusaini S., Shianna K.V., Radtke R.A. , Heinzen E.L., Walley N., Pandolfo M., Pichler W., Park B.K., Depondt C., Sisodiya S.M., Goldstein D.B., Deloukas P., Delanty N., Cavalleri G.L., Pirmohamed M.
N. Engl. J. Med. 364:1134-1143(2011) [PubMed] [Europe PMC] [Abstract]Cited for: ASSOCIATION OF ALLELE A*31:01 WITH CARBAMAZEPINE-INDUCED HYPERSENSITIVITY REACTIONS.
Mutagenesis
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| <p>This subsection of the <a href="http://www.uniprot.org/manual/pathology_and_biotech_section">'Pathology and Biotech'</a> section describes the effect of the experimental mutation of one or more amino acid(s) on the biological properties of the protein.<p><a href='/help/mutagen' target='_top'>More...</a></p>Mutagenesisi | 110 | N → Q: Impairs the recruitment of HLA-A*02 in the peptide-loading complex. 1 Publication Manual assertion based on experiment ini
| 1 | |
| Mutagenesisi | 156 | S → C: Impairs the maturation of a peptide-receptive HLA-A*02-B2M complex. 1 Publication Manual assertion based on experiment ini
| 1 | |
| Mutagenesisi | 158 | T → K: Impairs binding to TAP1-TAP2 transporter, resulting in impaired presentation of intracellular peptides. 2 Publications Manual assertion based on experiment ini
| 1 |
Organism-specific databases
Open Targets More...OpenTargetsi | ENSG00000206503 |
Orphanet; a database dedicated to information on rare diseases and orphan drugs More...Orphaneti | 179 Birdshot chorioretinopathy 414750 Phenytoin or carbamazepine toxicity |
The Pharmacogenetics and Pharmacogenomics Knowledge Base More...PharmGKBi | PA35055 |
Chemistry databases
Drug and drug target database More...DrugBanki | DB11294 Coccidioides immitis spherule DB06226 Nelipepimut-S |
<p>This section describes post-translational modifications (PTMs) and/or processing events.<p><a href='/help/ptm_processing_section' target='_top'>More...</a></p>PTM / Processingi
Molecule processing
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| <p>This subsection of the ‘PTM / Processing’ section denotes the presence of an N-terminal signal peptide.<p><a href='/help/signal' target='_top'>More...</a></p>Signal peptidei | 1 – 24 | 1 Publication Manual assertion based on experiment ini
| 24 | |
| <p>This subsection of the ‘PTM / Processing’ section describes the extent of a polypeptide chain in the mature protein following processing.<p><a href='/help/chain' target='_top'>More...</a></p>ChainiPRO_0000018815 | 25 – 365 | HLA class I histocompatibility antigen, A alpha chainAdd BLAST | 341 |
Amino acid modifications
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| <p>This subsection of the ‘PTM / Processing’ section specifies the position and type of each modified residue excluding <a href="http://www.uniprot.org/manual/lipid">lipids</a>, <a href="http://www.uniprot.org/manual/carbohyd">glycans</a> and <a href="http://www.uniprot.org/manual/crosslnk">protein cross-links</a>.<p><a href='/help/mod_res' target='_top'>More...</a></p>Modified residuei | 83 | SulfotyrosineSequence analysis | 1 | |
| <p>This subsection of the <a href="http://www.uniprot.org/help/ptm_processing_section">PTM / Processing</a> section specifies the position and type of each covalently attached glycan group (mono-, di-, or polysaccharide).<p><a href='/help/carbohyd' target='_top'>More...</a></p>Glycosylationi | 110 | N-linked (GlcNAc...) asparagine1 Publication Manual assertion based on experiment ini
| 1 | |
| <p>This subsection of the PTM / Processing":/help/ptm_processing_section section describes the positions of cysteine residues participating in disulfide bonds.<p><a href='/help/disulfid' target='_top'>More...</a></p>Disulfide bondi | 125 ↔ 188 | PROSITE-ProRule annotation <p>Manual validated information which has been generated by the UniProtKB automatic annotation system.</p> <p><a href="/manual/evidences#ECO:0000255">More...</a></p> Manual assertion according to rulesi 8 PublicationsManual assertion based on experiment ini
| ||
| Disulfide bondi | 227 ↔ 283 | PROSITE-ProRule annotation Manual assertion according to rulesi 8 PublicationsManual assertion based on experiment ini
| ||
| Modified residuei | 343 | PhosphoserineCombined sources <p>Manually validated information inferred from a combination of experimental and computational evidence.</p> <p><a href="/manual/evidences#ECO:0000244">More...</a></p> Manual assertion inferred from combination of experimental and computational evidencei
| 1 | |
| Modified residuei | 344 | PhosphotyrosineCombined sources Manual assertion inferred from combination of experimental and computational evidencei
| 1 | |
| Modified residuei | 349 | PhosphoserineCombined sources Manual assertion inferred from combination of experimental and computational evidencei
| 1 | |
| Modified residuei | 350 | PhosphoserineCombined sources Manual assertion inferred from combination of experimental and computational evidencei
| 1 | |
| Modified residuei | 352 | PhosphoserineCombined sources Manual assertion inferred from combination of experimental and computational evidencei
| 1 | |
| Modified residuei | 356 | PhosphoserineCombined sources Manual assertion inferred from combination of experimental and computational evidencei
| 1 | |
| Modified residuei | 359 | PhosphoserineCombined sources Manual assertion inferred from combination of experimental and computational evidencei
| 1 |
<p>This subsection of the <a href="http://www.uniprot.org/help/ptm_processing_section">PTM/processing</a> section describes post-translational modifications (PTMs). This subsection <strong>complements</strong> the information provided at the sequence level or describes modifications for which <strong>position-specific data is not yet available</strong>.<p><a href='/help/post-translational_modification' target='_top'>More...</a></p>Post-translational modificationi
(Microbial infection) Polyubiquitinated in a post ER compartment by interaction with human herpesvirus 8 MIR1 protein. This targets the protein for rapid degradation via the ubiquitin system.1 Publication
Manual assertion based on experiment ini
- Ref.50"Ubiquitylation of MHC class I by the K3 viral protein signals internalization and TSG101-dependent degradation."
Hewitt E.W., Duncan L., Mufti D., Baker J., Stevenson P.G., Lehner P.J.
EMBO J. 21:2418-2429(2002) [PubMed] [Europe PMC] [Abstract]Cited for: INTERACTION WITH HUMAN HERPESVIRUS 8 MIR1 PROTEIN (MICROBIAL INFECTION), UBIQUITINATION (MICROBIAL INFECTION).
N-linked glycosylation at Asn-110.2 Publications
Manual assertion based on experiment ini
- Ref.59"Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry."
Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.
J. Proteome Res. 8:651-661(2009) [PubMed] [Europe PMC] [Abstract]Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-110. - Ref.63"Distinct functions for the glycans of tapasin and heavy chains in the assembly of MHC class I molecules."
Rizvi S.M., Del Cid N., Lybarger L., Raghavan M.
J. Immunol. 186:2309-2320(2011) [PubMed] [Europe PMC] [Abstract]Cited for: INDUCTION BY IFNG, GLYCOSYLATION AT ASN-110, MUTAGENESIS OF ASN-110, SUBCELLULAR LOCATION, INTERACTION WITH TAPBP.
Keywords - PTMi
Disulfide bond, Glycoprotein, Phosphoprotein, Sulfation, Ubl conjugationProteomic databases
Encyclopedia of Proteome Dynamics More...EPDi | P04439 |
MaxQB - The MaxQuant DataBase More...MaxQBi | P04439 |
PeptideAtlas More...PeptideAtlasi | P04439 |
PRoteomics IDEntifications database More...PRIDEi | P04439 |
ProteomicsDB: a multi-organism proteome resource More...ProteomicsDBi | 51714 |
PTM databases
SwissPalm database of S-palmitoylation events More...SwissPalmi | P04439 |
<p>This section provides information on the expression of a gene at the mRNA or protein level in cells or in tissues of multicellular organisms.<p><a href='/help/expression_section' target='_top'>More...</a></p>Expressioni
<p>This subsection of the ‘Expression’ section provides information on the expression of a gene at the mRNA or protein level in cells or in tissues of multicellular organisms. By default, the information is derived from experiments at the mRNA level, unless specified ‘at protein level’. <br></br>Examples: <a href="http://www.uniprot.org/uniprot/P92958#expression">P92958</a>, <a href="http://www.uniprot.org/uniprot/Q8TDN4#expression">Q8TDN4</a>, <a href="http://www.uniprot.org/uniprot/O14734#expression">O14734</a><p><a href='/help/tissue_specificity' target='_top'>More...</a></p>Tissue specificityi
Ubiquitous.Curated
<p>This subsection of the ‘Expression’ section reports the experimentally proven effects of inducers and repressors (usually chemical compounds or environmental factors) on the level of protein (or mRNA) expression (up-regulation, down-regulation, constitutive expression).<p><a href='/help/induction' target='_top'>More...</a></p>Inductioni
Up-regulated by IFNG, and proinflammatory cytokines IL1B and TNF.2 Publications
Manual assertion based on experiment ini
- Ref.63"Distinct functions for the glycans of tapasin and heavy chains in the assembly of MHC class I molecules."
Rizvi S.M., Del Cid N., Lybarger L., Raghavan M.
J. Immunol. 186:2309-2320(2011) [PubMed] [Europe PMC] [Abstract]Cited for: INDUCTION BY IFNG, GLYCOSYLATION AT ASN-110, MUTAGENESIS OF ASN-110, SUBCELLULAR LOCATION, INTERACTION WITH TAPBP. - Ref.90"Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes."
Bulek A.M., Cole D.K., Skowera A., Dolton G., Gras S., Madura F., Fuller A., Miles J.J., Gostick E., Price D.A., Drijfhout J.W., Knight R.R., Huang G.C., Lissin N., Molloy P.E., Wooldridge L., Jakobsen B.K., Rossjohn J. , Peakman M., Rizkallah P.J., Sewell A.K.
Nat. Immunol. 13:283-289(2012) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.67 ANGSTROMS) OF 25-300 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, INTERACTION WITH TCR, FUNCTION (ALLELE A*02:01), DOMAIN, INDUCTION BY CYTOKINES, INVOLVEMENT IN IDDM (ALLELE A*02:01).
Gene expression databases
ExpressionAtlas, Differential and Baseline Expression More...ExpressionAtlasi | P04439 baseline and differential |
<p>This section provides information on the quaternary structure of a protein and on interaction(s) with other proteins or protein complexes.<p><a href='/help/interaction_section' target='_top'>More...</a></p>Interactioni
<p>This subsection of the <a href="http://www.uniprot.org/help/interaction_section">'Interaction'</a> section provides information about the protein quaternary structure and interaction(s) with other proteins or protein complexes (with the exception of physiological receptor-ligand interactions which are annotated in the <a href="http://www.uniprot.org/help/function_section">'Function'</a> section).<p><a href='/help/subunit_structure' target='_top'>More...</a></p>Subunit structurei
Heterotrimer that consists of an alpha chain HLA-A, a beta chain B2M and a peptide (peptide-HLA-A-B2M) (PubMed:7504010, PubMed:7679507, PubMed:21943705, PubMed:19177349, PubMed:24395804, PubMed:26758806, PubMed:7504010, PubMed:7506728, PubMed:8805302, PubMed:7694806, PubMed:7935798, PubMed:9177355, PubMed:18275829, PubMed:22245737, PubMed:28250417, PubMed:11502003, PubMed:8906788, PubMed:19542454). Early in biogenesis, HLA-A-B2M dimer interacts with the components of the peptide-loading complex composed of TAPBP, TAP1-TAP2, TAPBPL, PDIA3/ERP57 and CALR (PubMed:21263072).
Interacts with TAP1-TAP2 transporter via TAPBP; this interaction is obligatory for the loading of peptide epitopes delivered to the ER by TAP1-TAP2 transporter (PubMed:8805302, PubMed:8630735, PubMed:21263072).
Interacts with TAPBPL; TAPBPL binds peptide-free HLA-A-B2M complexes or those loaded with low affinity peptides, likely facilitating peptide exchange for higher affinity peptides (PubMed:26869717). Only optimally assembled peptide-HLA-B2M trimer translocates to the surface of antigen-presenting cells, where it interacts with TCR and CD8 coreceptor on the surface of T cells. HLA-A (via polymorphic alpha-1 and alpha-2 domains) interacts with antigen-specific TCR (via CDR3 domains) (PubMed:22245737, PubMed:12796775, PubMed:18275829). One HLA-A molecule (mainly via nonpolymorphic alpha-3 domain) interacts with one CD8A homodimer (via CDR-like loop); this interaction insures peptide-HLA-A-B2M recognition by CD8-positive T cells only (PubMed:9177355, PubMed:2784196). Alleles A*23:01; A*24:02 and A*32:01 interact (via Bw4 motif) with KIR3DL1 on NK cells; this interaction is direct.
22 PublicationsManual assertion based on experiment ini
- Ref.38"Polymorphism in the alpha 3 domain of HLA-A molecules affects binding to CD8."
Salter R.D., Norment A.M., Chen B.P., Clayberger C., Krensky A.M., Littman D.R., Parham P.
Nature 338:345-347(1989) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES A*02:01 AND A*68:01), INTERACTION WITH CD8A, DOMAIN, CHARACTERIZATION OF VARIANT VAL-269. - Ref.40"HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs."
DiBrino M., Tsuchida T., Turner R.V., Parker K.C., Coligan J.E., Biddison W.E.
J. Immunol. 151:5930-5935(1993) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES A*01:01 AND A*03:01), INTERACTION WITH B2M AND PEPTIDE. - Ref.41"Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides."
DiBrino M., Parker K.C., Shiloach J., Knierman M., Lukszo J., Turner R.V., Biddison W.E., Coligan J.E.
Proc. Natl. Acad. Sci. U.S.A. 90:1508-1512(1993) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*03:01), INTERACTION WITH B2M AND PEPTIDE. - Ref.42"Endogenous peptides with distinct amino acid anchor residue motifs bind to HLA-A1 and HLA-B8."
DiBrino M., Parker K.C., Shiloach J., Turner R.V., Tsuchida T., Garfield M., Biddison W.E., Coligan J.E.
J. Immunol. 152:620-631(1994) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*01:01), INTERACTION WITH B2M AND PEPTIDE. - Ref.43"Point mutations in the alpha 2 domain of HLA-A2.1 define a functionally relevant interaction with TAP."
Lewis J.W., Neisig A., Neefjes J., Elliott T.
Curr. Biol. 6:873-883(1996) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*02:01), MUTAGENESIS OF SER-156 AND THR-158, DOMAIN, INTERACTION WITH B2M, INTERACTION WITH TAP1-TAP2 COMPLEX, SUBCELLULAR LOCATION. - Ref.44"A point mutation in HLA-A*0201 results in failure to bind the TAP complex and to present virus-derived peptides to CTL."
Peace-Brewer A.L., Tussey L.G., Matsui M., Li G., Quinn D.G., Frelinger J.A.
Immunity 4:505-514(1996) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*02:01), INTERACTION WITH TAP1-TAP2 COMPLEX, MUTAGENESIS OF THR-158. - Ref.55"Cutting Edge: Allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B."
Thananchai H., Gillespie G., Martin M.P., Bashirova A., Yawata N., Yawata M., Easterbrook P., McVicar D.W., Maenaka K., Parham P., Carrington M., Dong T., Rowland-Jones S.
J. Immunol. 178:33-37(2007) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES A*23:01; A*24:02 AND A*32:01), INTERACTION WITH KIR3DL1. - Ref.57"Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1."
Stern M., Ruggeri L., Capanni M., Mancusi A., Velardi A.
Blood 112:708-710(2008) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*24:02), INTERACTION WITH KIR3DL1. - Ref.63"Distinct functions for the glycans of tapasin and heavy chains in the assembly of MHC class I molecules."
Rizvi S.M., Del Cid N., Lybarger L., Raghavan M.
J. Immunol. 186:2309-2320(2011) [PubMed] [Europe PMC] [Abstract]Cited for: INDUCTION BY IFNG, GLYCOSYLATION AT ASN-110, MUTAGENESIS OF ASN-110, SUBCELLULAR LOCATION, INTERACTION WITH TAPBP. - Ref.70"Interaction of TAPBPR, a tapasin homolog, with MHC-I molecules promotes peptide editing."
Morozov G.I., Zhao H., Mage M.G., Boyd L.F., Jiang J., Dolan M.A., Venna R., Norcross M.A., McMurtrey C.P., Hildebrand W., Schuck P., Natarajan K., Margulies D.H.
Proc. Natl. Acad. Sci. U.S.A. 113:E1006-E1015(2016) [PubMed] [Europe PMC] [Abstract]Cited for: INTERACTION WITH TAPBPL. - Ref.76"The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2."
Madden D.R., Garboczi D.N., Wiley D.C.
Cell 75:693-708(1993) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 25-299 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*02:01), DISULFIDE BOND, DOMAIN. - Ref.77"Three-dimensional structure of a peptide extending from one end of a class I MHC binding site."
Collins E.J., Garboczi D.N., Wiley D.C.
Nature 371:626-629(1994) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 25-299 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*02:01). - Ref.79"Crystal structure of the complex between human CD8alpha(alpha) and HLA-A2."
Gao G.F., Tormo J., Gerth U.C., Wyer J.R., McMichael A.J., Stuart D.I., Bell J.I., Jones E.Y., Jakobsen B.K.
Nature 387:630-634(1997) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 25-300 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, INTERACTION WITH CD8A, FUNCTION (ALLELE A*02:01). - Ref.80"High-resolution structure of HLA-A*0201 in complex with a tumour-specific antigenic peptide encoded by the MAGE-A4 gene."
Hillig R.C., Coulie P.G., Stroobant V., Saenger W., Ziegler A., Hulsmeyer M.
J. Mol. Biol. 310:1167-1176(2001) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.40 ANGSTROMS) OF 25-299 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*02:01). - Ref.81"A structural basis for immunodominant human T cell receptor recognition."
Stewart-Jones G.B.E., McMichael A.J., Bell J.I., Stuart D.I., Jones E.Y.
Nat. Immunol. 4:657-663(2003) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.40 ANGSTROMS) OF 25-300 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, INTERACTION WITH TCR, FUNCTION (ALLELE A*02:01). - Ref.83"The structural dynamics and energetics of an immunodominant T cell receptor are programmed by its Vbeta domain."
Ishizuka J., Stewart-Jones G.B., van der Merwe A., Bell J.I., McMichael A.J., Jones E.Y.
Immunity 28:171-182(2008) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 25-300 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, INTERACTION WITH TCR, FUNCTION (ALLELE A*02:01). - Ref.85"Conformational changes within the HLA-A1:MAGE-A1 complex induced by binding of a recombinant antibody fragment with TCR-like specificity."
Kumar P., Vahedi-Faridi A., Saenger W., Ziegler A., Uchanska-Ziegler B.
Protein Sci. 18:37-49(2009) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 25-298 (ALLELE A*01:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*01:01), DOMAIN, DISULFIDE BOND. - Ref.89"Structural basis of cross-allele presentation by HLA-A*0301 and HLA-A*1101 revealed by two HIV-derived peptide complexes."
Zhang S., Liu J., Cheng H., Tan S., Qi J., Yan J., Gao G.F.
Mol. Immunol. 49:395-401(2011) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 25-298 (ALLELE A*03:01) IN COMPLEX WITH B2M AND PEPTIDE, DISULFIDE BOND, DOMAIN, FUNCTION (ALLELE A*03:01). - Ref.90"Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes."
Bulek A.M., Cole D.K., Skowera A., Dolton G., Gras S., Madura F., Fuller A., Miles J.J., Gostick E., Price D.A., Drijfhout J.W., Knight R.R., Huang G.C., Lissin N., Molloy P.E., Wooldridge L., Jakobsen B.K., Rossjohn J. , Peakman M., Rizkallah P.J., Sewell A.K.
Nat. Immunol. 13:283-289(2012) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.67 ANGSTROMS) OF 25-300 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, INTERACTION WITH TCR, FUNCTION (ALLELE A*02:01), DOMAIN, INDUCTION BY CYTOKINES, INVOLVEMENT IN IDDM (ALLELE A*02:01). - Ref.91"Preexisting CD8+ T-cell immunity to the H7N9 influenza A virus varies across ethnicities."
Quinones-Parra S., Grant E., Loh L., Nguyen T.H., Campbell K.A., Tong S.Y., Miller A., Doherty P.C., Vijaykrishna D., Rossjohn J., Gras S., Kedzierska K.
Proc. Natl. Acad. Sci. U.S.A. 111:1049-1054(2014) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 25-308 (ALLELE A*01:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*01:01), DOMAIN. - Ref.92"Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy."
Raman M.C., Rizkallah P.J., Simmons R., Donnellan Z., Dukes J., Bossi G., Le Provost G.S., Todorov P., Baston E., Hickman E., Mahon T., Hassan N., Vuidepot A., Sami M., Cole D.K., Jakobsen B.K.
Sci. Rep. 6:18851-18851(2016) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 25-298 (ALLELE A*01:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*01:01), DOMAIN, DISULFIDE BOND. - Ref.93"Broad TCR repertoire and diverse structural solutions for recognition of an immunodominant CD8+ T cell epitope."
Song I., Gil A., Mishra R., Ghersi D., Selin L.K., Stern L.J.
Nat. Struct. Mol. Biol. 24:395-406(2017) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.06 ANGSTROMS) OF 25-299 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*02:01), DOMAIN, DISULFIDE BOND.
(Microbial infection) Interacts with HHV-8 MIR1 protein.
1 PublicationManual assertion based on experiment ini
- Ref.50"Ubiquitylation of MHC class I by the K3 viral protein signals internalization and TSG101-dependent degradation."
Hewitt E.W., Duncan L., Mufti D., Baker J., Stevenson P.G., Lehner P.J.
EMBO J. 21:2418-2429(2002) [PubMed] [Europe PMC] [Abstract]Cited for: INTERACTION WITH HUMAN HERPESVIRUS 8 MIR1 PROTEIN (MICROBIAL INFECTION), UBIQUITINATION (MICROBIAL INFECTION).
(Microbial infection) Interacts with HTLV-1 accessory protein p12I.
1 PublicationManual assertion based on experiment ini
- Ref.49"Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I) protein."
Johnson J.M., Nicot C., Fullen J., Ciminale V., Casareto L., Mulloy J.C., Jacobson S., Franchini G.
J. Virol. 75:6086-6094(2001) [PubMed] [Europe PMC] [Abstract]Cited for: INTERACTION WITH HTLV-1 ACCESSORY PROTEIN P12I (MICROBIAL INFECTION).
GO - Molecular functioni
- beta-2-microglobulin binding Source: UniProtKB
- TAP binding Source: UniProtKBInferred from direct assayi
- "Allele-specific differences in the interaction of MHC class I molecules with transporters associated with antigen processing."
Neisig A., Wubbolts R., Zang X., Melief C., Neefjes J.
J. Immunol. 156:3196-3206(1996) [PubMed] [Europe PMC] [Abstract]
Protein-protein interaction databases
The Biological General Repository for Interaction Datasets (BioGrid) More...BioGridi | 109350, 106 interactors |
Protein interaction database and analysis system More...IntActi | P04439, 30 interactors |
Molecular INTeraction database More...MINTi | P04439 |
Chemistry databases
BindingDB database of measured binding affinities More...BindingDBi | P04439 |
<p>This section provides information on the tertiary and secondary structure of a protein.<p><a href='/help/structure_section' target='_top'>More...</a></p>Structurei
3D structure databases
SWISS-MODEL Repository - a database of annotated 3D protein structure models More...SMRi | P04439 |
Database of comparative protein structure models More...ModBasei | Search... |
Protein Data Bank in Europe - Knowledge Base More...PDBe-KBi | Search... |
<p>This section provides information on sequence similarities with other proteins and the domain(s) present in a protein.<p><a href='/help/family_and_domains_section' target='_top'>More...</a></p>Family & Domainsi
Domains and Repeats
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| <p>This subsection of the <a href="http://www.uniprot.org/help/family_and_domains_section">Family and Domains</a> section describes the position and type of a domain, which is defined as a specific combination of secondary structures organized into a characteristic three-dimensional structure or fold.<p><a href='/help/domain' target='_top'>More...</a></p>Domaini | 209 – 295 | Ig-like C1-typeSequence analysisAdd BLAST | 87 |
Region
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| <p>This subsection of the ‘Family and Domains’ section describes a region of interest that cannot be described in other subsections.<p><a href='/help/region' target='_top'>More...</a></p>Regioni | 25 – 114 | Alpha-1Sequence analysisAdd BLAST | 90 | |
| Regioni | 115 – 206 | Alpha-2Sequence analysisAdd BLAST | 92 | |
| Regioni | 207 – 298 | Alpha-3Sequence analysisAdd BLAST | 92 | |
| Regioni | 299 – 308 | Connecting peptideSequence analysis | 10 |
<p>This subsection of the ‘Family and domains’ section provides general information on the biological role of a domain. The term ‘domain’ is intended here in its wide acceptation, it may be a structural domain, a transmembrane region or a functional domain. Several domains are described in this subsection.<p><a href='/help/domain_cc' target='_top'>More...</a></p>Domaini
The alpha-1 domain is a structural part of the peptide-binding cleft.11 Publications
Manual assertion based on experiment ini
- Ref.38"Polymorphism in the alpha 3 domain of HLA-A molecules affects binding to CD8."
Salter R.D., Norment A.M., Chen B.P., Clayberger C., Krensky A.M., Littman D.R., Parham P.
Nature 338:345-347(1989) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES A*02:01 AND A*68:01), INTERACTION WITH CD8A, DOMAIN, CHARACTERIZATION OF VARIANT VAL-269. - Ref.76"The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2."
Madden D.R., Garboczi D.N., Wiley D.C.
Cell 75:693-708(1993) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 25-299 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*02:01), DISULFIDE BOND, DOMAIN. - Ref.78"Structure of the complex between human T-cell receptor, viral peptide and HLA-A2."
Garboczi D.N., Ghosh P., Utz U., Fan Q.R., Biddison W.E., Wiley D.C.
Nature 384:134-141(1996) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 25-299 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*02:01), DOMAIN. - Ref.84"Structural bases for the affinity-driven selection of a public TCR against a dominant human cytomegalovirus epitope."
Gras S., Saulquin X., Reiser J.B., Debeaupuis E., Echasserieau K., Kissenpfennig A., Legoux F., Chouquet A., Le Gorrec M., Machillot P., Neveu B., Thielens N., Malissen B., Bonneville M., Housset D.
J. Immunol. 183:430-437(2009) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 25-298 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*02:01), DOMAIN. - Ref.85"Conformational changes within the HLA-A1:MAGE-A1 complex induced by binding of a recombinant antibody fragment with TCR-like specificity."
Kumar P., Vahedi-Faridi A., Saenger W., Ziegler A., Uchanska-Ziegler B.
Protein Sci. 18:37-49(2009) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 25-298 (ALLELE A*01:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*01:01), DOMAIN, DISULFIDE BOND. - Ref.86"Novel immunodominant peptide presentation strategy: a featured HLA-A*2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein."
Liu J., Wu P., Gao F., Qi J., Kawana-Tachikawa A., Xie J., Vavricka C.J., Iwamoto A., Li T., Gao G.F.
J. Virol. 84:11849-11857(2010) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 25-298 (ALLELE A*24:02) IN COMPLEX WITH B2M AND WITH SARS NUCLEOCAPSID PEPTIDE, DISULFIDE BONDS, FUNCTION (ALLELE A*24:02), DOMAIN. - Ref.87"Structures of native and affinity-enhanced WT1 epitopes bound to HLA-A*0201: implications for WT1-based cancer therapeutics."
Borbulevych O.Y., Do P., Baker B.M.
Mol. Immunol. 47:2519-2524(2010) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.89 ANGSTROMS) OF 25-299 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*02:01), DOMAIN. - Ref.89"Structural basis of cross-allele presentation by HLA-A*0301 and HLA-A*1101 revealed by two HIV-derived peptide complexes."
Zhang S., Liu J., Cheng H., Tan S., Qi J., Yan J., Gao G.F.
Mol. Immunol. 49:395-401(2011) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 25-298 (ALLELE A*03:01) IN COMPLEX WITH B2M AND PEPTIDE, DISULFIDE BOND, DOMAIN, FUNCTION (ALLELE A*03:01). - Ref.90"Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes."
Bulek A.M., Cole D.K., Skowera A., Dolton G., Gras S., Madura F., Fuller A., Miles J.J., Gostick E., Price D.A., Drijfhout J.W., Knight R.R., Huang G.C., Lissin N., Molloy P.E., Wooldridge L., Jakobsen B.K., Rossjohn J. , Peakman M., Rizkallah P.J., Sewell A.K.
Nat. Immunol. 13:283-289(2012) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.67 ANGSTROMS) OF 25-300 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, INTERACTION WITH TCR, FUNCTION (ALLELE A*02:01), DOMAIN, INDUCTION BY CYTOKINES, INVOLVEMENT IN IDDM (ALLELE A*02:01). - Ref.91"Preexisting CD8+ T-cell immunity to the H7N9 influenza A virus varies across ethnicities."
Quinones-Parra S., Grant E., Loh L., Nguyen T.H., Campbell K.A., Tong S.Y., Miller A., Doherty P.C., Vijaykrishna D., Rossjohn J., Gras S., Kedzierska K.
Proc. Natl. Acad. Sci. U.S.A. 111:1049-1054(2014) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 25-308 (ALLELE A*01:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*01:01), DOMAIN. - Ref.92"Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy."
Raman M.C., Rizkallah P.J., Simmons R., Donnellan Z., Dukes J., Bossi G., Le Provost G.S., Todorov P., Baston E., Hickman E., Mahon T., Hassan N., Vuidepot A., Sami M., Cole D.K., Jakobsen B.K.
Sci. Rep. 6:18851-18851(2016) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 25-298 (ALLELE A*01:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*01:01), DOMAIN, DISULFIDE BOND.
The alpha-2 domain is a structural part of the peptide-binding cleft (PubMed:21543847, PubMed:21943705, PubMed:19177349, PubMed:26758806, PubMed:24395804, PubMed:7694806, PubMed:8906788, PubMed:2784196, PubMed:28250417, PubMed:22245737, PubMed:19542454, PubMed:20619457, PubMed:20844028). Mediates the interaction with TAP1-TAP2 complex (PubMed:8805302).14 Publications
Manual assertion based on experiment ini
- Ref.38"Polymorphism in the alpha 3 domain of HLA-A molecules affects binding to CD8."
Salter R.D., Norment A.M., Chen B.P., Clayberger C., Krensky A.M., Littman D.R., Parham P.
Nature 338:345-347(1989) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES A*02:01 AND A*68:01), INTERACTION WITH CD8A, DOMAIN, CHARACTERIZATION OF VARIANT VAL-269. - Ref.43"Point mutations in the alpha 2 domain of HLA-A2.1 define a functionally relevant interaction with TAP."
Lewis J.W., Neisig A., Neefjes J., Elliott T.
Curr. Biol. 6:873-883(1996) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELE A*02:01), MUTAGENESIS OF SER-156 AND THR-158, DOMAIN, INTERACTION WITH B2M, INTERACTION WITH TAP1-TAP2 COMPLEX, SUBCELLULAR LOCATION. - Ref.76"The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2."
Madden D.R., Garboczi D.N., Wiley D.C.
Cell 75:693-708(1993) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 25-299 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*02:01), DISULFIDE BOND, DOMAIN. - Ref.78"Structure of the complex between human T-cell receptor, viral peptide and HLA-A2."
Garboczi D.N., Ghosh P., Utz U., Fan Q.R., Biddison W.E., Wiley D.C.
Nature 384:134-141(1996) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 25-299 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*02:01), DOMAIN. - Ref.84"Structural bases for the affinity-driven selection of a public TCR against a dominant human cytomegalovirus epitope."
Gras S., Saulquin X., Reiser J.B., Debeaupuis E., Echasserieau K., Kissenpfennig A., Legoux F., Chouquet A., Le Gorrec M., Machillot P., Neveu B., Thielens N., Malissen B., Bonneville M., Housset D.
J. Immunol. 183:430-437(2009) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 25-298 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*02:01), DOMAIN. - Ref.85"Conformational changes within the HLA-A1:MAGE-A1 complex induced by binding of a recombinant antibody fragment with TCR-like specificity."
Kumar P., Vahedi-Faridi A., Saenger W., Ziegler A., Uchanska-Ziegler B.
Protein Sci. 18:37-49(2009) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 25-298 (ALLELE A*01:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*01:01), DOMAIN, DISULFIDE BOND. - Ref.86"Novel immunodominant peptide presentation strategy: a featured HLA-A*2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein."
Liu J., Wu P., Gao F., Qi J., Kawana-Tachikawa A., Xie J., Vavricka C.J., Iwamoto A., Li T., Gao G.F.
J. Virol. 84:11849-11857(2010) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 25-298 (ALLELE A*24:02) IN COMPLEX WITH B2M AND WITH SARS NUCLEOCAPSID PEPTIDE, DISULFIDE BONDS, FUNCTION (ALLELE A*24:02), DOMAIN. - Ref.87"Structures of native and affinity-enhanced WT1 epitopes bound to HLA-A*0201: implications for WT1-based cancer therapeutics."
Borbulevych O.Y., Do P., Baker B.M.
Mol. Immunol. 47:2519-2524(2010) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.89 ANGSTROMS) OF 25-299 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*02:01), DOMAIN. - Ref.88"Structure of HLA-A*0301 in complex with a peptide of proteolipid protein: insights into the role of HLA-A alleles in susceptibility to multiple sclerosis."
McMahon R.M., Friis L., Siebold C., Friese M.A., Fugger L., Jones E.Y.
Acta Crystallogr. D 67:447-454(2011) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 25-298 (ALLELE A*03:01) IN COMPLEX WITH B2M AND PLP1 ANTIGENIC PEPTIDE, DISULFIDE BONDS, DOMAIN. - Ref.89"Structural basis of cross-allele presentation by HLA-A*0301 and HLA-A*1101 revealed by two HIV-derived peptide complexes."
Zhang S., Liu J., Cheng H., Tan S., Qi J., Yan J., Gao G.F.
Mol. Immunol. 49:395-401(2011) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 25-298 (ALLELE A*03:01) IN COMPLEX WITH B2M AND PEPTIDE, DISULFIDE BOND, DOMAIN, FUNCTION (ALLELE A*03:01). - Ref.90"Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes."
Bulek A.M., Cole D.K., Skowera A., Dolton G., Gras S., Madura F., Fuller A., Miles J.J., Gostick E., Price D.A., Drijfhout J.W., Knight R.R., Huang G.C., Lissin N., Molloy P.E., Wooldridge L., Jakobsen B.K., Rossjohn J. , Peakman M., Rizkallah P.J., Sewell A.K.
Nat. Immunol. 13:283-289(2012) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (1.67 ANGSTROMS) OF 25-300 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, INTERACTION WITH TCR, FUNCTION (ALLELE A*02:01), DOMAIN, INDUCTION BY CYTOKINES, INVOLVEMENT IN IDDM (ALLELE A*02:01). - Ref.91"Preexisting CD8+ T-cell immunity to the H7N9 influenza A virus varies across ethnicities."
Quinones-Parra S., Grant E., Loh L., Nguyen T.H., Campbell K.A., Tong S.Y., Miller A., Doherty P.C., Vijaykrishna D., Rossjohn J., Gras S., Kedzierska K.
Proc. Natl. Acad. Sci. U.S.A. 111:1049-1054(2014) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 25-308 (ALLELE A*01:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*01:01), DOMAIN. - Ref.92"Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy."
Raman M.C., Rizkallah P.J., Simmons R., Donnellan Z., Dukes J., Bossi G., Le Provost G.S., Todorov P., Baston E., Hickman E., Mahon T., Hassan N., Vuidepot A., Sami M., Cole D.K., Jakobsen B.K.
Sci. Rep. 6:18851-18851(2016) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 25-298 (ALLELE A*01:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*01:01), DOMAIN, DISULFIDE BOND. - Ref.93"Broad TCR repertoire and diverse structural solutions for recognition of an immunodominant CD8+ T cell epitope."
Song I., Gil A., Mishra R., Ghersi D., Selin L.K., Stern L.J.
Nat. Struct. Mol. Biol. 24:395-406(2017) [PubMed] [Europe PMC] [Abstract]Cited for: X-RAY CRYSTALLOGRAPHY (2.06 ANGSTROMS) OF 25-299 (ALLELE A*02:01) IN COMPLEX WITH B2M AND PEPTIDE, FUNCTION (ALLELE A*02:01), DOMAIN, DISULFIDE BOND.
The alpha-3 Ig-like domain mediates the interaction with CD8 coreceptor.1 Publication
Manual assertion based on experiment ini
- Ref.38"Polymorphism in the alpha 3 domain of HLA-A molecules affects binding to CD8."
Salter R.D., Norment A.M., Chen B.P., Clayberger C., Krensky A.M., Littman D.R., Parham P.
Nature 338:345-347(1989) [PubMed] [Europe PMC] [Abstract]Cited for: FUNCTION (ALLELES A*02:01 AND A*68:01), INTERACTION WITH CD8A, DOMAIN, CHARACTERIZATION OF VARIANT VAL-269.
<p>This subsection of the ‘Family and domains’ section provides information about the sequence similarity with other proteins.<p><a href='/help/sequence_similarities' target='_top'>More...</a></p>Sequence similaritiesi
Belongs to the MHC class I family.Curated
Keywords - Domaini
Immunoglobulin domain, Signal, Transmembrane, Transmembrane helixPhylogenomic databases
KEGG Orthology (KO) More...KOi | K06751 |
Family and domain databases
Gene3D Structural and Functional Annotation of Protein Families More...Gene3Di | 2.60.40.10, 1 hit 3.30.500.10, 1 hit |
Integrated resource of protein families, domains and functional sites More...InterProi | View protein in InterPro IPR007110 Ig-like_dom IPR036179 Ig-like_dom_sf IPR013783 Ig-like_fold IPR003006 Ig/MHC_CS IPR003597 Ig_C1-set IPR011161 MHC_I-like_Ag-recog IPR037055 MHC_I-like_Ag-recog_sf IPR011162 MHC_I/II-like_Ag-recog IPR001039 MHC_I_a_a1/a2 IPR010579 MHC_I_a_C |
Pfam protein domain database More...Pfami | View protein in Pfam PF07654 C1-set, 1 hit PF00129 MHC_I, 1 hit PF06623 MHC_I_C, 1 hit |
Protein Motif fingerprint database; a protein domain database More...PRINTSi | PR01638 MHCCLASSI |
Simple Modular Architecture Research Tool; a protein domain database More...SMARTi | View protein in SMART SM00407 IGc1, 1 hit |
Superfamily database of structural and functional annotation More...SUPFAMi | SSF48726 SSF48726, 1 hit SSF54452 SSF54452, 1 hit |
<p>This section displays by default the canonical protein sequence and upon request all isoforms described in the entry. It also includes information pertinent to the sequence(s), including <a href="http://www.uniprot.org/help/sequence_length">length</a> and <a href="http://www.uniprot.org/help/sequences">molecular weight</a>. The information is filed in different subsections. The current subsections and their content are listed below:<p><a href='/help/sequences_section' target='_top'>More...</a></p>Sequences (2+)i
<p>This subsection of the <a href="http://www.uniprot.org/help/sequences_section">Sequence</a> section indicates if the <a href="http://www.uniprot.org/help/canonical_and_isoforms">canonical sequence</a> displayed by default in the entry is complete or not.<p><a href='/help/sequence_status' target='_top'>More...</a></p>Sequence statusi: Complete.
<p>This subsection of the <a href="http://www.uniprot.org/help/sequences_section">Sequence</a> section indicates if the <a href="http://www.uniprot.org/help/canonical_and_isoforms">canonical sequence</a> displayed by default in the entry is in its mature form or if it represents the precursor.<p><a href='/help/sequence_processing' target='_top'>More...</a></p>Sequence processingi: The displayed sequence is further processed into a mature form.
This entry describes 2 <p>This subsection of the ‘Sequence’ section lists the alternative protein sequences (isoforms) that can be generated from the same gene by a single or by the combination of up to four biological events (alternative promoter usage, alternative splicing, alternative initiation and ribosomal frameshifting). Additionally, this section gives relevant information on each alternative protein isoform.<p><a href='/help/alternative_products' target='_top'>More...</a></p> isoformsi produced by alternative splicing. AlignAdd to basketAdded to basketThis entry has 2 described isoforms and 27 potential isoforms that are computationally mapped.Show allAlign All
Isoform 1 (identifier: P04439-1) [UniParc]FASTAAdd to basketAdded to basket
This isoform has been chosen as the <div> <p><b>What is the canonical sequence?</b><p><a href='/help/canonical_and_isoforms' target='_top'>More...</a></p>canonicali sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry.
« Hide
Show »10 20 30 40 50
MAVMAPRTLL LLLSGALALT QTWAGSHSMR YFFTSVSRPG RGEPRFIAVG
60 70 80 90 100
YVDDTQFVRF DSDAASQRME PRAPWIEQEG PEYWDQETRN VKAQSQTDRV
110 120 130 140 150
DLGTLRGYYN QSEAGSHTIQ IMYGCDVGSD GRFLRGYRQD AYDGKDYIAL
160 170 180 190 200
NEDLRSWTAA DMAAQITKRK WEAAHEAEQL RAYLDGTCVE WLRRYLENGK
210 220 230 240 250
ETLQRTDPPK THMTHHPISD HEATLRCWAL GFYPAEITLT WQRDGEDQTQ
260 270 280 290 300
DTELVETRPA GDGTFQKWAA VVVPSGEEQR YTCHVQHEGL PKPLTLRWEL
310 320 330 340 350
SSQPTIPIVG IIAGLVLLGA VITGAVVAAV MWRRKSSDRK GGSYTQAASS
360
DSAQGSDVSL TACKV
Length:365
Mass (Da):40,841
Last modified:August 22, 2003 - v2
<p>The checksum is a form of redundancy check that is calculated
from the sequence. It is useful for tracking sequence updates.</p>
<p>It should be noted that while, in theory, two different sequences could
have the same checksum value, the likelihood that this would happen
is extremely low.</p>
<p>However UniProtKB may contain entries with identical sequences in case
of multiple genes (paralogs).</p>
<p>The checksum is computed as the sequence 64-bit Cyclic Redundancy Check value (CRC64)
using the generator polynomial: x<sup>64</sup> + x<sup>4</sup> + x<sup>3</sup> + x + 1.
The algorithm is described in the ISO 3309 standard.
</p>
<p class="publication">Press W.H., Flannery B.P., Teukolsky S.A. and Vetterling W.T.<br />
<strong>Cyclic redundancy and other checksums</strong><br />
<a href="http://www.nrbook.com/b/bookcpdf.php">Numerical recipes in C 2nd ed., pp896-902, Cambridge University Press (1993)</a>)</p>
Checksum:iDEDFCEC4450E0580
Isoform 2 (identifier: P04439-2) [UniParc]FASTAAdd to basketAdded to basket
The sequence of this isoform differs from the canonical sequence as follows:
176-187: EAEQLRAYLDGT → AAEQQRAYLEGR
337-337: S → SGGEGVK
« Hide
Show »10 20 30 40 50
MAVMAPRTLL LLLSGALALT QTWAGSHSMR YFFTSVSRPG RGEPRFIAVG
60 70 80 90 100
YVDDTQFVRF DSDAASQRME PRAPWIEQEG PEYWDQETRN VKAQSQTDRV
110 120 130 140 150
DLGTLRGYYN QSEAGSHTIQ IMYGCDVGSD GRFLRGYRQD AYDGKDYIAL
160 170 180 190 200
NEDLRSWTAA DMAAQITKRK WEAAHAAEQQ RAYLEGRCVE WLRRYLENGK
210 220 230 240 250
ETLQRTDPPK THMTHHPISD HEATLRCWAL GFYPAEITLT WQRDGEDQTQ
260 270 280 290 300
DTELVETRPA GDGTFQKWAA VVVPSGEEQR YTCHVQHEGL PKPLTLRWEL
310 320 330 340 350
SSQPTIPIVG IIAGLVLLGA VITGAVVAAV MWRRKSSGGE GVKDRKGGSY
360 370
TQAASSDSAQ GSDVSLTACK V
<p>In eukaryotic reference proteomes, unreviewed entries that are likely to belong to the same gene are computationally mapped, based on gene identifiers from Ensembl, EnsemblGenomes and model organism databases.<p><a href='/help/gene_centric_isoform_mapping' target='_top'>More...</a></p>Computationally mapped potential isoform sequencesi
There are 27 potential isoforms mapped to this entry.BLASTAlignShow allAdd to basket| Entry | Entry name | Protein names | Gene names | Length | Annotation | ||
|---|---|---|---|---|---|---|---|
| B0UXQ0 | B0UXQ0_HUMAN | HLA class I histocompatibility anti... HLA class I histocompatibility antigen, A-3 alpha chain (MHC class I antigen) (MHC class I protein) | HLA-A HLA | 365 | Annotation score: Annotation score:2 out of 5 <p>The annotation score provides a heuristic measure of the annotation content of a UniProtKB entry or proteome. This score <strong>cannot</strong> be used as a measure of the accuracy of the annotation as we cannot define the ‘correct annotation’ for any given protein.<p><a href='/help/annotation_score' target='_top'>More...</a></p> | ||
| Q5SRN5 | Q5SRN5_HUMAN | HLA class I histocompatibility anti... HLA class I histocompatibility antigen, A-3 alpha chain | HLA-A | 371 | Annotation score: Annotation score:2 out of 5 <p>The annotation score provides a heuristic measure of the annotation content of a UniProtKB entry or proteome. This score <strong>cannot</strong> be used as a measure of the accuracy of the annotation as we cannot define the ‘correct annotation’ for any given protein.<p><a href='/help/annotation_score' target='_top'>More...</a></p> | ||
| A0A140T9X5 | A0A140T9X5_HUMAN | HLA class I histocompatibility anti... HLA class I histocompatibility antigen, A-3 alpha chain | HLA-A | 371 | Annotation score: Annotation score:2 out of 5 <p>The annotation score provides a heuristic measure of the annotation content of a UniProtKB entry or proteome. This score <strong>cannot</strong> be used as a measure of the accuracy of the annotation as we cannot define the ‘correct annotation’ for any given protein.<p><a href='/help/annotation_score' target='_top'>More...</a></p> | ||
| A0A140T913 | A0A140T913_HUMAN | HLA class I histocompatibility anti... HLA class I histocompatibility antigen, A-3 alpha chain | HLA-A | 371 | Annotation score: Annotation score:2 out of 5 <p>The annotation score provides a heuristic measure of the annotation content of a UniProtKB entry or proteome. This score <strong>cannot</strong> be used as a measure of the accuracy of the annotation as we cannot define the ‘correct annotation’ for any given protein.<p><a href='/help/annotation_score' target='_top'>More...</a></p> | ||
| A0A140T8Y4 | A0A140T8Y4_HUMAN | HLA class I histocompatibility anti... HLA class I histocompatibility antigen, A-3 alpha chain | HLA-A | 371 | Annotation score: Annotation score:2 out of 5 <p>The annotation score provides a heuristic measure of the annotation content of a UniProtKB entry or proteome. This score <strong>cannot</strong> be used as a measure of the accuracy of the annotation as we cannot define the ‘correct annotation’ for any given protein.<p><a href='/help/annotation_score' target='_top'>More...</a></p> | ||
| A0A0G2JIF2 | A0A0G2JIF2_HUMAN | HLA class I histocompatibility anti... HLA class I histocompatibility antigen, A-3 alpha chain | HLA-A | 371 | Annotation score: Annotation score:2 out of 5 <p>The annotation score provides a heuristic measure of the annotation content of a UniProtKB entry or proteome. This score <strong>cannot</strong> be used as a measure of the accuracy of the annotation as we cannot define the ‘correct annotation’ for any given protein.<p><a href='/help/annotation_score' target='_top'>More...</a></p> | ||
| A0A0G2JPD3 | A0A0G2JPD3_HUMAN | HLA class I histocompatibility anti... HLA class I histocompatibility antigen, A-3 alpha chain | HLA-A | 394 | Annotation score: Annotation score:2 out of 5 <p>The annotation score provides a heuristic measure of the annotation content of a UniProtKB entry or proteome. This score <strong>cannot</strong> be used as a measure of the accuracy of the annotation as we cannot define the ‘correct annotation’ for any given protein.<p><a href='/help/annotation_score' target='_top'>More...</a></p> | ||
| A0A140T9I0 | A0A140T9I0_HUMAN | HLA class I histocompatibility anti... HLA class I histocompatibility antigen, A-3 alpha chain | HLA-A | 365 | Annotation score: Annotation score:2 out of 5 <p>The annotation score provides a heuristic measure of the annotation content of a UniProtKB entry or proteome. This score <strong>cannot</strong> be used as a measure of the accuracy of the annotation as we cannot define the ‘correct annotation’ for any given protein.<p><a href='/help/annotation_score' target='_top'>More...</a></p> | ||
| A0A1W2PSE7 | A0A1W2PSE7_HUMAN | HLA class I histocompatibility anti... HLA class I histocompatibility antigen, A-3 alpha chain | HLA-A | 367 | Annotation score: Annotation score:2 out of 5 <p>The annotation score provides a heuristic measure of the annotation content of a UniProtKB entry or proteome. This score <strong>cannot</strong> be used as a measure of the accuracy of the annotation as we cannot define the ‘correct annotation’ for any given protein.<p><a href='/help/annotation_score' target='_top'>More...</a></p> | ||
| Q9GJ45 | Q9GJ45_HUMAN | HLA class I histocompatibility anti... HLA class I histocompatibility antigen, A-3 alpha chain (MHC class I antigen) | HLA-A | 326 | Annotation score: Annotation score:2 out of 5 <p>The annotation score provides a heuristic measure of the annotation content of a UniProtKB entry or proteome. This score <strong>cannot</strong> be used as a measure of the accuracy of the annotation as we cannot define the ‘correct annotation’ for any given protein.<p><a href='/help/annotation_score' target='_top'>More...</a></p> | ||
| There are more potential isoformsShow all | |||||||
<p>This subsection of the ‘Sequence’ section reports difference(s) between the protein sequence shown in the UniProtKB entry and other available protein sequences derived from the same gene.<p><a href='/help/sequence_caution' target='_top'>More...</a></p>Sequence cautioni
The sequence CAA25162 differs from that shown. Reason: Erroneous gene model prediction.1 Publication
Manual assertion inferred by curator fromi
- Ref.19"Complete nucleotide sequence of a functional class I HLA gene, HLA-A3: implications for the evolution of HLA genes."
Strachan T., Sodoyer R., Damotte M., Jordan B.R.
EMBO J. 3:887-894(1984) [PubMed] [Europe PMC] [Abstract]Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE A*03:01).
<p>This subsection of the ‘Sequence’ section provides information on polymorphic variants. If the variant is associated with a disease state, the description of the latter can be found in the <a href="http://www.uniprot.org/manual/involvement_in_disease">'Involvement in disease'</a> subsection.<p><a href='/help/polymorphism' target='_top'>More...</a></p>Polymorphismi
Highly polymorphic. Polymorphic residues encode for alpha-1 and alpha-2 domains of the peptide-binding cleft, where they contribute to variations in peptide binding and TCR recognition among different alleles. The human population is estimated to have millions of HLA-A alleles. But only 11 common HLA-A alleles are considered core alleles, representing all functionally significant variation (polymorphism) in alpha-1 and alpha-2 domains. These are: A*01:01; A*02:01; A*02:05; A*03:01; A*11:01; A*24:02; A*26:01; A*29:02; A*30:01; A*74:01 and A*80:01. Among these, A*02:01; A*11:01; A*24:02 and A*26:01, were likely passed by introgression from archaic to modern humans. Functional alleles of more recent origin (non-core) were derived by recombination (PubMed:28650991). The sequence shown is that of A*03:01. The sequences of core alleles and common representative alleles of serologically distinct allele groups are described as variants of A*03:01.Curated1 Publication
Manual assertion based on experiment ini
- Ref.102"Distinguishing functional polymorphism from random variation in the sequences of >10,000 HLA-A, -B and -C alleles."
Robinson J., Guethlein L.A., Cereb N., Yang S.Y., Norman P.J., Marsh S.G.E., Parham P.
PLoS Genet. 13:E1006862-E1006862(2017) [PubMed] [Europe PMC] [Abstract]Cited for: POLYMORPHISM.
Natural variant
| Feature key | Position(s) | DescriptionActions | Graphical view | Length |
|---|---|---|---|---|
| <p>This subsection of the ‘Sequence’ section describes natural variant(s) of the protein sequence.<p><a href='/help/variant' target='_top'>More...</a></p>Natural variantiVAR_082315 | 3 | V → I in allele A*34:01. 1 Publication Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082316 | 5 | A → P in allele A*80:01. 2 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082317 | 10 | L → V in allele A*02:01, allele A*02:05, allele A*23:01, allele A*24:02, allele A*25:01, allele A*26:01, allele A*34:01, allele A*43:01, allele A*66:01, allele A*68:01 and allele A*69:01. 10 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082318 | 14 | S → L in allele A*29:02, allele A*31:01, allele A*32:01, allele A*33:01 and allele A*74:01. 7 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082319 | 23 | W → R in allele A*74:01. 1 Publication Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082320 | 33 | F → S in allele A*23:01, allele A*24:02 and allele A*30:01. 4 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082321 | 33 | F → T in allele A*29:02, allele A*31:01 and allele A*33:01; requires 2 nucleotide substitutions. 4 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082322 | 33 | F → Y in allele A*02:05, allele A*11:01, allele A*25:01, allele A*26:01, allele A*34:01, allele A*43:01, allele A*66:01, allele A*68:01 and allele A*69:01. 9 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082323 | 41 | R → S in allele A*30:01. 2 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082324 | 55 | T → S in allele A*80:01. 2 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082325 | 59 | R → Q in allele A*80:01. 2 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082326 | 67 | Q → R in allele A*02:05. 1 Publication Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082327 | 68 | R → K in alleles A*01:01 and allele A*36:01. 4 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082328 | 80 | G → E in allele A*80:01. 2 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082329 | 80 | G → R in allele A*30:01 and allele A*31:01. 4 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082330 | 86 | Q → E in allele A*23:01, allele 24:02 and allele A*80:01. 4 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082331 | 86 | Q → G in allele A*02:01 and allele A*02:05; requires 2 nucleotide substitutions. 4 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082332 | 86 | Q → L in alleles A*29:02 and allele A*43:01. 2 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082333 | 86 | Q → R in allele A*25:01, allele A*26:01, allele A*33:01, allele A*34:01, allele A*66:01, allele A*68:01 and allele A*69:01. 6 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082334 | 87 | E → N in alleles A*25:01, allele A*26:01, allele A*33:01, allele A*34:01, allele A*66:01, allele A*68:01 and allele A*69:01; requires 2 nucleotide substitutions. 6 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082335 | 87 | E → Q in allele A*29:02 and allele A*43:01. 2 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082336 | 89 | R → G in allele A*23:01 and allele 24:02. 2 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082337 | 90 | N → K in allele A*02:01, allele A*02:05, allele A*23:01, allele 24:02 and allele A*34:01. 7 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082338 | 91 | V → M in allele A*01:01 and allele A*36:01. 4 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082339 | 94 | Q → H in allele A*01:01, allele A*02:01, allele A*02:05, allele A*23:01, allele 24:02, allele A*25:01, allele A*26:01, allele A*31:01, allele A*32:01, allele A*33:01, allele A*36:01, allele A*43:01, allele A*74:01 and allele A*80:01. 19 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082340 | 97 | T → I in allele A*31:01 and allele A*33:01. 3 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082341 | 98 | D → H in allele A*02:01 and allele A*02:05. 4 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082342 | 98 | D → N in allele A*80:01. 2 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082343 | 100 | V → A in allele A*01:01, allele A*26:01, allele A*29:02, allele A*36:01, allele A*43:01 and allele A*80:01. 9 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082344 | 100 | V → E in allele A*23:01, allele A*24:02, allele A*25:01 and allele A*32:01. 5 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082345 | 101 | D → N Allele A*01:01, allele A*23:01, allele A*24:02, allele A*26:01, allele A*29:02, allele A*36:01, allele A*43:01 and allele A*80:01. 11 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082346 | 101 | D → S in allele A*25:01 and allele A*32:01; requires 2 nucleotide substitutions. 3 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082347 | 103 – 107 | GTLRG → RIALR in allele A*23:01, allele A*24:02, allele A*25:01 and allele A*32:01; Bw4 motif RIALR is involved in the recognition of NK cell inhibitory receptor KIR3DL1. 7 Publications Manual assertion based on experiment ini
| 5 | |
| Natural variantiVAR_082348 | 114 | A → D in allele A*01:01, allele A*11:01, allele A*25:01, allele A*26:01, allele A*34:01, allele A*36:01, allele A*43:01, allele A*66:01 and allele A*80:01. 12 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082349 | 119 | I → L in allele A*02:05, allele A*23:01 and allele 24:02. 3 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082350 | 119 | I → V in allele A*02:01 and allele A*69:01. 4 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082351 | 121 | I → M in allele A*23:01, allele 24:02, allele A*29:02, allele A*31:01, allele A*32:01, allele A*33:01, allele A*68:01 and allele A*74:01. 10 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082352 | 121 | I → R in allele A*02:01, allele A*02:05, allele A*25:01, allele A*26:01, allele A*34:01, allele A*43:01, allele A*66:01 and allele A*69:01. 8 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082353 | 123 | Y → F in allele A*23:01, allele 24:02. 2 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082354 | 129 | S → P in allele A*01:01, allele A*11:01, allele A*25:01, allele A*26:01, allele A*32:01, allele A*34:01, allele A*36:01, allele A*43:01, allele A*66:01 and allele A*74:01. 12 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082355 | 131 | G → W in allele A*02:01, allele A*02:05 and allele A*69:01. 5 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082356 | 133 | F → L in allele A*32:01 and allele A*74:01. 3 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082357 | 138 | R → E in allele A*30:01; requires 2 nucleotide substitutions. 2 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082358 | 138 | R → H in allele A*02:01, allele A*02:05, allele A*23:01, allele A*24:02, allele A*69:01. 7 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082359 | 138 | R → Q in allele A*25:01, allele A*26:01, allele A*31:01, allele A*32:01, allele A*33:01, allele A*34:01, allele A*43:01, allele A*66:01, allele A*74:01. 9 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082360 | 140 | D → H in allele A*30:01. 2 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082361 | 140 | D → Y in allele A*02:01, allele A*02:05, allele A*23:01, allele A*24:02 and allele A*69:01. 7 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082362 | 151 | N → K in allele A*02:01, allele A*02:05, allele A*23:01, allele A*24:02, allele A*68:01 and allele A*69:01. 7 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082363 | 166 | I → T in allele A*02:01, allele A*02:05, allele A*68:01 and allele A*69:01. 5 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082364 | 168 | K → Q in allele A*23:01, allele A*25:01, allele A*26:01, allele A*29:02, allele A*30:01, allele A*31:01, allele A*32:01, allele A*33:01, allele A*34:01, allele A*43:01, allele A*66:01 and allele A*74:01. 12 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082365 | 169 | R → H in allele A*02:01, allele A*02:05, allele A*68:01 and allele A*69:01. 5 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082366 | 173 | A → T in allele A*25:01, allele A*26:01, allele A*34:01, allele A*43:01 and allele A*66:01. 4 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082367 | 174 | A → V in allele A*01:01 and allele A*36:01. 4 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082368 | 175 | H → R in allele A*23:01, allele A*29:02, allele A*30:01, allele A*31:01, allele A*32:01, allele A*33:01, allele A*74:01 and allele A*80:01. 11 Publications Manual assertion based on experiment ini
| 1 | |
| Natural variantiVAR_082369 | 176 | E → A in allele A*01:01, allele A*11:01 and allele A*36:01. 7 Publications Manual assertion based on experiment ini
|